AngioDynamics (ANGO) 10-K 10 Aug 20 2020 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	May 31, 2020	Aug. 05, 2020	Nov. 30, 2019
Cover [Abstract]
Entity Central Index Key	0001275187
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--05-31
Document Type	10-K
Document Annual Report	true
Document Period End Date	May 31, 2020
Document Transition Report	false
Entity File Number	0-50761
Entity Registrant Name	AngioDynamics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3146460
Entity Address, Address Line One	14 Plaza Drive
Entity Address, City or Town	Latham
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	12110
City Area Code	518
Local Phone Number	795-1400
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	ANGO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 531,215,389
Entity Common Stock, Shares Outstanding		37,869,430
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCEThe information required for Part III of this Annual Report on Form 10-K is incorporated by reference to the registrant’s Proxy Statement for its 2020 Annual Meeting of Stockholders to be filed within 120 days of the registrant's fiscal year ended May 31, 2020.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	May 31, 2020
Equity [Abstract]
Schedule summarizes stock option activity	The following table summarizes information about stock option activity for the fiscal year ended May 31, 2020: Shares Weighted average exercise price Weighted average remaining contractual life Aggregate intrinsic value (in thousands) Outstanding at beginning of year - June 1, 2019 1,760,313 $ 16.54 Granted 539,946 $ 18.92 Exercised (61,100) $ 12.67 Forfeited (300,406) $ 17.81 Expired Outstanding at end of year - May 31, 2020 1,938,753 $ 16.89 6.00 $ — Options exercisable at year-end 1,004,531 $ 15.63 3.70 $ — Options expected to vest in future periods 934,222 $ 18.25 8.40 $ —
Share based compensation arrangement by share based payment award nonvested shares and weighted average grant date fair value	The following table summarizes information about restricted stock unit activity for the year ended May 31, 2020: Restricted Stock Units Weighted Average Grant-Date Fair Value Non-vested at beginning of year, June 1, 2019 430,936 $ 18.60 Granted 278,064 $ 20.35 Vested (197,985) $ 19.75 Canceled (46,094) $ 19.68 Non-vested at end of year, May 31, 2020 464,921 $ 19.65 The following table summarizes information about performance unit award activity for the year ended May 31, 2020: Performance Unit Awards Weighted Average Grant-Date Fair Value Non-vested at beginning of year, June 1, 2019 538,605 $ 21.55 Granted 111,594 $ 14.06 Vested (235,580) $ 21.68 Canceled (141,498) $ 20.86 Non-vested at end of year, May 31, 2020 273,121 $ 22.07
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following tables represents the break out of share-based compensation included in the Company's consolidated statement of operations: Year ended May 31, (in thousands) 2020 2019 2018 Cost of sales $ 655 $ 461 $ 119 Research and development 971 724 554 Sales and marketing 1,665 1,952 1,778 General and administrative 4,302 6,112 5,461 $ 7,593 $ 9,249 $ 7,912

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Income Statement [Abstract]
Net sales	$ 264,157	$ 270,634	$ 261,655
Cost of sales (exclusive of intangible amortization)	113,885	114,634	117,799
Gross profit	150,272	156,000	143,856
Operating expenses
Research and development	29,682	28,258	24,338
Sales and marketing	78,634	76,829	73,109
General and administrative	37,872	34,902	30,991
Amortization of intangibles	18,121	17,056	13,906
Goodwill impairment	158,578	0	0
Change in fair value of contingent consideration	(11,531)	(6,776)	250
Acquisition, restructuring and other items, net	6,014	15,127	15,432
Total operating expenses	317,370	165,396	158,026
Operating loss	(167,098)	(9,396)	(14,170)
Other expenses
Interest expense, net	(907)	(5,099)	(3,062)
Other expense	(130)	(207)	(31)
Total other expenses, net	(1,037)	(5,306)	(3,093)
Loss from continuing operations before income tax benefit	(168,135)	(14,702)	(17,263)
Income tax benefit	(1,348)	(3,556)	(11,036)
Net loss from continuing operations	(166,787)	(11,146)	(6,227)
Income from discontinued operations, net of income tax	0	72,486	22,562
Net income (loss)	$ (166,787)	$ 61,340	$ 16,335
Loss per share - continuing operations
Basic (usd per share)	$ (4.39)	$ (0.30)	$ (0.17)
Diluted (usd per share)	(4.39)	(0.30)	(0.17)
Income per share - discontinued operations
Basic (usd per share)	0	1.93	0.61
Diluted (usd per share)	0	1.93	0.61
Income (loss) per share
Basic (usd per share)	(4.39)	1.64	0.44
Diluted (usd per share)	$ (4.39)	$ 1.64	$ 0.44
Weighted average shares outstanding
Basic (in shares)	37,961,224	37,484,573	37,074,797
Diluted (in shares)	37,961,224	37,484,573	37,074,797

Consolidated Statements Compreh

Consolidated Statements Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (166,787)	$ 61,340	$ 16,335
Other comprehensive income (loss), before tax:
Unrealized gain on marketable securities	0	33	102
Reclassification adjustment for gains included in net income	0	(116)	0
Foreign currency translation gain (loss)	11	(317)	270
Other comprehensive income (loss), before tax	11	(400)	372
Income tax benefit (expense) related to items of other comprehensive income (loss)	0	0	0
Other comprehensive income (loss), net of tax	11	(400)	372
Total comprehensive income (loss), net of tax	$ (166,776)	$ 60,940	$ 16,707

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Current Assets
Cash and cash equivalents	$ 54,435	$ 227,641
Accounts receivable, net of allowances of $2,150 and $1,906, respectively	31,263	43,577
Inventories	59,905	40,071
Prepaid expenses and other	7,310	4,003
Total current assets	152,913	315,292
Property, plant and equipment, net	28,312	24,258
Other assets	15,338	3,835
Intangible assets, net	197,136	145,387
Goodwill	200,515	347,666
Total Assets	594,214	836,438
Current Liabilities
Accounts payable	19,096	22,829
Accrued liabilities	29,380	38,338
Current portion of long-term debt	0	7,500
Current portion of contingent consideration	836	4,635
Other current liabilities	2,133	0
Total current liabilities	51,445	73,302
Long-term debt, net of current portion	40,000	124,407
Deferred income taxes	24,057	14,542
Contingent consideration, net of current portion	14,811	8,851
Other long-term liabilities	9,029	521
Total Liabilities	139,342	221,623
Commitments and Contingencies (Note 17)
Stockholders’ Equity
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 38,448,536 and 37,984,382 shares issued and 38,078,536 and 37,614,382 shares outstanding at May 31, 2020 and 2019, respectively	374	372
Additional paid-in capital	561,871	555,040
Retained earnings	(100,318)	66,469
Treasury stock, 370,000 shares, at cost at May 31, 2020 and 2019, respectively	(5,714)	(5,714)
Accumulated other comprehensive loss	(1,341)	(1,352)
Total Stockholders' Equity	454,872	614,815
Total Liabilities and Stockholders' Equity	$ 594,214	$ 836,438

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 2,150	$ 1,906
Preferred stock, par value (usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)	5,000,000	5,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (shares)	75,000,000	75,000,000
Common stock, shares issued (shares)	38,448,536	37,984,382
Common stock, shares outstanding (shares)	38,078,536	37,614,382
Treasury stock, shares (shares)	370,000,000	370,000,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Restricted Stock Units	Performance Shares	Common Stock	Common StockRestricted Stock Units	Common StockPerformance Shares	Additional paid in capital	Additional paid in capitalCumulative Effect, Period of Adoption, Adjustment	Additional paid in capitalRestricted Stock Units	Retained earnings (accumulated deficit)	Retained earnings (accumulated deficit)Cumulative Effect, Period of Adoption, Adjustment	Accumulated other comprehensive loss	Treasury Stock
Beginning Balance, Shares at May. 31, 2017					37,210,091									(370,000)
Beginning Balance at May. 31, 2017	$ 515,027	$ 0			$ 367			$ 532,705	$ 199		$ (11,007)	$ (199)	$ (1,324)	$ (5,714)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	16,335										16,335
Exercise of stock options, Shares					148,937
Exercise of stock options	1,917				$ 1			1,916
Issuance/cancellation of common stock units, Shares						145,522
Issuance/cancellation of common stock units			$ (231)			$ 1				$ (232)
Purchase of common stock under Employee Stock Purchase Plan, Shares					89,943
Purchase of common stock under Employee Stock Purchase Plan	1,263				$ 1			1,262
Stock-based compensation	7,912							7,912
Other comprehensive income (loss), net of tax	372												372
Ending Balance at May. 31, 2018	542,595				$ 370			543,762			5,129		(952)	$ (5,714)
Ending Balance, Shares at May. 31, 2018					37,594,493									(370,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	61,340										61,340
Exercise of stock options, Shares					134,253
Exercise of stock options	1,526				$ 1			1,525
Issuance/cancellation of common stock units, Shares						177,538	5,235
Issuance/cancellation of common stock units			(667)	$ 0						(667)
Purchase of common stock under Employee Stock Purchase Plan, Shares					72,863
Purchase of common stock under Employee Stock Purchase Plan	1,172				$ 1			1,171
Stock-based compensation	9,249							9,249
Other comprehensive income (loss), net of tax	(400)												(400)
Ending Balance at May. 31, 2019	614,815				$ 372			555,040			66,469		(1,352)	$ (5,714)
Ending Balance, Shares at May. 31, 2019					37,984,382									(370,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ (166,787)										(166,787)
Exercise of stock options, Shares	61,100				50,636
Exercise of stock options	$ 561				$ 1			560
Issuance/cancellation of common stock units, Shares						312,951
Issuance/cancellation of common stock units			$ (2,537)							$ (2,537)
Purchase of common stock under Employee Stock Purchase Plan, Shares					100,567
Purchase of common stock under Employee Stock Purchase Plan	1,217				$ 1			1,216
Stock-based compensation	7,592							7,592
Other comprehensive income (loss), net of tax	11												11
Ending Balance at May. 31, 2020	$ 454,872				$ 374			$ 561,871			$ (100,318)		$ (1,341)	$ (5,714)
Ending Balance, Shares at May. 31, 2020					38,448,536									(370,000)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Cash flows from operating activities:
Net income (loss)	$ (166,787)	$ 61,340	$ 16,335
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	23,805	25,880	23,163
Goodwill impairment	158,578	0	0
Stock based compensation	7,592	9,249	7,912
Gain on disposition	0	(46,592)	0
Transaction costs for disposition	0	(4,030)	0
Change in fair value of contingent consideration	(11,531)	(6,776)	250
Deferred income tax provision	(1,568)	(2,655)	(8,947)
Changes in accounts receivable allowances	429	(202)	179
Asset impairments and disposals	1,321	2,495	540
Other	86	(5)	(605)
Changes in operating assets and liabilities:
Accounts receivable	11,918	(3,177)	5,044
Inventories	(18,845)	(1,428)	5,740
Prepaid expenses and other	(6,155)	(1,871)	(1,231)
Accounts payable, accrued and other liabilities	(15,467)	5,212	(7,093)
Net cash provided by (used in) operating activities	(14,554)	37,440	41,287
Cash flows from investing activities:
Additions to property, plant and equipment	(7,235)	(3,118)	(2,391)
Proceeds from disposition of discontinued operations	0	169,242	0
Cash paid for acquisitions	(55,760)	(84,920)	0
Acquisition of intangibles	(350)	0	(1,265)
Proceeds from sale of marketable securities	0	1,350	0
Net cash provided by (used in) investing activities	(63,345)	82,554	(3,656)
Cash flows from financing activities:
Repayment of long-term debt	(132,500)	(15,000)	(5,000)
Proceeds from borrowings on revolving credit facility	40,000	55,000	0
Deferred financing costs on long-term debt	(775)	0	0
Payment of acquisition related contingent consideration	(1,208)	(8,100)	(9,500)
Proceeds (outlays) from exercise of stock options and employee stock purchase plan	(759)	2,031	2,949
Net cash provided by (used in) financing activities	(95,242)	33,931	(11,551)
Effect of exchange rate changes on cash and cash equivalents	(65)	(380)	472
(Decrease) increase in cash and cash equivalents	(173,206)	153,545	26,552
Cash and cash equivalents at beginning of year	227,641	74,096	47,544
Cash and cash equivalents at end of year	54,435	227,641	74,096
Supplemental disclosure of non-cash investing and financing activities:
Increase (decrease) in accounts payable for purchases of fixed assets	224	(114)	56
Fair value of contingent consideration for acquisitions	14,900	25,100	0
Fair value of acquisition consideration included in accrued expenses	0	4,650	0
Cash paid during the year for:
Interest	413	5,115	3,190
Income taxes	682	426	36
Noncash Lease Expense	$ 2,070	$ 0	$ 0

Quarterly Information (unaudite

Quarterly Information (unaudited)	12 Months Ended
	May 31, 2020
Quarterly Financial Information Disclosure [Abstract]
QUARTERLY INFORMATION (unaudited)	QUARTERLY INFORMATION (unaudited) Quarterly results of operations during the fiscal years ended May 31, 2020 and 2019 are as follows: 2020 (in thousands, except per share data) First quarter Second quarter Third quarter Fourth quarter Net sales $ 66,042 $ 70,003 $ 69,780 $ 58,332 Gross profit 38,217 41,544 40,299 30,212 Net loss (1) $ (1,275) $ (2,736) $ (5,709) $ (157,067) Earnings per share net income Basic $ (0.03) $ (0.07) $ (0.15) $ (4.14) Diluted $ (0.03) $ (0.07) $ (0.15) $ (4.14) (1) Net loss in the fourth quarter of fiscal year 2020 included the goodwill impairment charge of 158.6 million . 2019 (in thousands, except per share data) First quarter Second quarter Third quarter Fourth quarter Net sales $ 63,943 $ 69,985 $ 65,524 $ 71,182 Gross profit 35,953 40,552 38,163 41,332 Net income (loss) from continuing operations (5,704) (3,587) (4,609) 2,753 Net income from discontinued operations 5,235 5,727 5,405 56,120 Net income (loss) (1) $ (469) $ 2,140 $ 796 $ 58,873 Loss per share from continuing operations Basic $ (0.15) $ (0.10) $ (0.12) $ 0.07 Diluted $ (0.15) $ (0.10) $ (0.12) $ 0.07 Earnings per share from discontinued operations Basic $ 0.14 $ 0.15 $ 0.14 $ 1.49 Diluted $ 0.14 $ 0.15 $ 0.14 $ 1.47 Earnings per share net income Basic $ (0.01) $ 0.06 $ 0.02 $ 1.57 Diluted $ (0.01) $ 0.06 $ 0.02 $ 1.54 (1) Net income in the fourth quarter of fiscal year 2019 was driven by the gain on the sale of the Fluid Management business. The data in the schedules above has been intentionally rounded to the nearest thousand and therefore the quarterly amounts may not sum to the full year amounts.

Quarterly Information (unaudi_2

Quarterly Information (unaudited) (Tables)	12 Months Ended
	May 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Information	Quarterly results of operations during the fiscal years ended May 31, 2020 and 2019 are as follows: 2020 (in thousands, except per share data) First quarter Second quarter Third quarter Fourth quarter Net sales $ 66,042 $ 70,003 $ 69,780 $ 58,332 Gross profit 38,217 41,544 40,299 30,212 Net loss (1) $ (1,275) $ (2,736) $ (5,709) $ (157,067) Earnings per share net income Basic $ (0.03) $ (0.07) $ (0.15) $ (4.14) Diluted $ (0.03) $ (0.07) $ (0.15) $ (4.14) (1) Net loss in the fourth quarter of fiscal year 2020 included the goodwill impairment charge of 158.6 million . 2019 (in thousands, except per share data) First quarter Second quarter Third quarter Fourth quarter Net sales $ 63,943 $ 69,985 $ 65,524 $ 71,182 Gross profit 35,953 40,552 38,163 41,332 Net income (loss) from continuing operations (5,704) (3,587) (4,609) 2,753 Net income from discontinued operations 5,235 5,727 5,405 56,120 Net income (loss) (1) $ (469) $ 2,140 $ 796 $ 58,873 Loss per share from continuing operations Basic $ (0.15) $ (0.10) $ (0.12) $ 0.07 Diluted $ (0.15) $ (0.10) $ (0.12) $ 0.07 Earnings per share from discontinued operations Basic $ 0.14 $ 0.15 $ 0.14 $ 1.49 Diluted $ 0.14 $ 0.15 $ 0.14 $ 1.47 Earnings per share net income Basic $ (0.01) $ 0.06 $ 0.02 $ 1.57 Diluted $ (0.01) $ 0.06 $ 0.02 $ 1.54 (1) Net income in the fourth quarter of fiscal year 2019 was driven by the gain on the sale of the Fluid Management business.

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	May 31, 2020	May 31, 2018
Statement of Stockholders' Equity [Abstract]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201602Member	us-gaap:AccountingStandardsUpdate201609Member

Basis of Presentation, Business

Basis of Presentation, Business Description and Summary of Significant Accounting Policies	12 Months Ended
	May 31, 2020
Accounting Policies [Abstract]
BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Description of Business The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the “Company”). The Company designs, manufactures and sells a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and in oncology and surgical settings. The devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use. On May 31, 2019, the Company completed the sale of the Fluid Management business and all of the assets used primarily in connection with the Fluid Management business (Note 3). As the disposal of this business represents a strategic shift with a major effect on the Company's operations, for all periods presented in the Consolidated Statements of Operations and Comprehensive Income, all sales, costs, expenses, gains and income taxes attributable to Fluid Management have been reported under the captions, “Income from Discontinued Operations, Net of Income Tax.” Cash flows used in or provided by Fluid Management have been reported in the Consolidated Statements of Cash Flows under operating and investing activities. Accounting Principles The consolidated financial statements and accompanying notes have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Principles of Consolidation The consolidated financial statements include the accounts of AngioDynamics and its subsidiaries (all of which are wholly owned). All intercompany balances and transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all unrestricted highly liquid investments with an initial maturity of less than three months at the date of purchase to be cash equivalents. The Company maintains cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation. Fair Value Instruments The carrying amount of the Company's cash and cash equivalents, accounts receivable, accounts payable and long-term debt approximates fair value due to the short-term nature or market interest rates of these items. The Company bases the fair value of short-term investments on quoted market prices or other relevant information generated by market transactions involving identical or comparable assets. The Company measures and records derivative financial instruments at fair value. See Note 5 for further discussion of financial instruments that are carried at fair value on a recurring and nonrecurring basis. Accounts Receivable Accounts receivable, principally trade receivables, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for estimated sales returns and doubtful accounts. The Company performs ongoing credit evaluations of customers and adjusts credit limits based upon payment history and the customer’s current creditworthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations Inventories Inventories are stated at the lower of cost (using the first-in, first-out method) or market. Appropriate consideration is given to deterioration, obsolescence, expiring and other factors in evaluating net realizable value. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Refer below for useful lives by category: Estimated useful lives Building and building improvements 39 years Machinery and equipment 5 to 8 years Computer software and equipment 3 to 5 years The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized. Contingent Consideration The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods and reflective of the risk associated with the estimated cash flow streams. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved. Revenue Recognition The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services. See Note 4, “Revenue from Contracts with Customers” for further discussion on revenue. Research and Development Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred. Income Taxes The Company calculates income tax expense for each jurisdiction in which it operates. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. The Company periodically evaluates deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on the Company's ability to generate future taxable income and capital gains. Where it is more-likely-than-not these will not be recovered, the Company estimates a valuation allowance and records a corresponding additional tax expense in the consolidated statement of operations. The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return utilizing a two-step approach. The Company first determines if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is that the Company measures the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes on the consolidated statements of operations. Foreign Currency Translation The functional currency of the Company's foreign subsidiaries is the local currency in which the subsidiary operates. For foreign operations where the local currency is considered to be the functional currency, the Company translates assets and liabilities into U.S. dollars at the exchange rate on the balance sheet date. The Company translates income and expense items at average rates of exchange prevailing during each period. The Company accumulates translation adjustments in accumulated other comprehensive loss, a component of stockholders’ equity. Transaction gains or losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in other expense in the statements of operations as incurred. Derivative Financial Instruments The Company is exposed to market risks, including changes in foreign currency and interest rates. The Company periodically enters into certain derivative financial instruments to hedge the underlying economic exposure. Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders’ equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the Contingencies The Company is subject to various legal proceedings that arise in the ordinary course of business, including patent infringement and product liability matters. The Company records accruals for contingencies when it is probable the liability has been incurred and the amount can be reasonably estimated. Legal fees are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. These recoveries are not netted against the related liabilities for financial statement presentation. The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: Recently Issued Accounting Pronouncements - Adopted Standard Description Date Adopted Effect on the Consolidated Financial Statements ASU 2016-02, Leases (Topic 842) This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. June 1, 2019 Refer to Note 16, Leases, for the required disclosures related to adopting this standard. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2018-13, Fair Value Measurement (Topic 820) This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes. June 1, 2020 The Company plans to adopt the new standard in the first quarter of fiscal year 2021 and does not expect there to be a material impact to the consolidated financial statements. ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. June 1, 2020 The Company plans to adopt the new standard in the first quarter of fiscal year 2021 and does not expect there to be a material impact to the consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	May 31, 2020
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS C3 Wave Tip Location Acquisition On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc. for an aggregate purchase price of $10.0 million with $5.0 million of potential future contingent consideration related to technical milestones. This acquisition fills a gap in the Vascular Access portfolio and supports the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory of $0.6 million and intangible assets of a trademark of $0.9 million and product technology of $8.5 million. The intangible assets will be amortized over 15 years. The contingent consideration is comprised of technical milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable. Eximo Acquisition On October 2, 2019, the Company entered into a share purchase agreement to acquire Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm laser atherectomy technology. The aggregate purchase price of $60.7 million included an upfront payment of $45.8 million and contingent consideration with an estimated fair value of $14.9 million. This acquisition expands and complements the Company’s Vascular Interventions and Therapies product portfolio by adding the 355nm laser atherectomy technology which treats Peripheral Artery Disease. The Company accounted for the Eximo acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is non-deductible for income tax purposes. The Company has not disclosed the amount of revenue and earnings for sales of Eximo products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the Eximo acquisition, which are included in "acquisition, restructuring and other items, net" in the accompanying Consolidated Statements of Operations, were approximately $0.6 million in fiscal year 2020. The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired: (in thousands) Preliminary allocation Adjustments (1) Final allocation Accounts receivable $ 50 $ — $ 50 Inventory 150 — 150 Prepaid and other current assets 54 — 54 Long-term deposits 51 51 Property, plant and equipment 397 — 397 Intangible assets: Product technology 59,000 1,300 60,300 Goodwill 12,428 (1,001) 11,427 Total assets acquired $ 72,130 $ 299 $ 72,429 Liabilities assumed Accounts payable $ 84 $ — $ 84 Other current liabilities 615 — 615 Deferred tax liabilities 10,771 299 11,070 Total liabilities assumed $ 11,470 $ 299 $ 11,769 Net assets acquired $ 60,660 $ — $ 60,660 (1) Measurement period adjustments are recognized on a prospective basis in the period of change, instead of restating prior periods. There was no impact to reported earnings in connection with these measurement period adjustments for the periods presented. Amounts represent adjustments to the preliminary purchase price allocation first presented in the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2019 resulting from revising the Company's purchase price allocation for this acquisition. The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of fiscal year 2020. The value assigned to the product technology was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. The product technology is deemed to have a useful life of fifteen years and will be amortized on a straight-line basis over the useful life. The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations. RadiaDyne Acquisition On September 21, 2018, the Company acquired RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes. The aggregate purchase price of $75.0 million included an upfront payment of $47.9 million, contingent consideration with an estimated fair value of $22.3 million, an indemnification holdback of $4.6 million and a purchase price holdback of $0.2 million. The fair value of contingent consideration of $22.3 million is comprised of $16.5 million for the revenue milestones and $5.8 million for the technical milestones. The indemnification holdback is recorded in accrued liabilities at May 31, 2020 and the purchase price holdback was initially recorded in accrued liabilities, but was paid during the third quarter of fiscal year 2019. This acquisition expands the Company’s growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies. The Company accounted for the RadiaDyne acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes. The Company has not disclosed the amount of revenue and earnings for sales of RadiaDyne products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the RadiaDyne acquisition, which are included in "acquisition, restructuring and other items, net" in the accompanying Consolidated Statements of Operations, were approximately $1.6 million in fiscal year 2019. The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired: (in thousands) Final allocation Accounts receivable $ 900 Inventory 732 Prepaid and other current assets 98 Property, plant and equipment 133 Intangible assets: RadiaDyne trademark 400 OARtrac trademark 200 RadiaDyne legacy product technology 1,500 OARtrac product technology 18,900 RadiaDyne customer relationships 4,600 Goodwill 47,982 Total assets acquired $ 75,445 Liabilities assumed Accounts payable $ 352 Accrued expenses 106 Total liabilities assumed $ 458 Net assets acquired $ 74,987 The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of fiscal year 2019. The values assigned to the RadiaDyne and OARtrac trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademarks are deemed to have a useful life of five seven The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over fifteen years. The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations. BioSentry Acquisition On August 14, 2018, the Company acquired the BioSentry product from Surgical Specialties, LLC (“SSC”), for an aggregate purchase price of $39.8 million of which $37.0 million was paid on August 14, 2018 and $2.8 million was recorded as contingent consideration. The contingent consideration liability was recorded at fair value and was paid in the fourth quarter of fiscal year 2019 upon fulfillment of hydrogel orders by SSC. The Company accounted for the BioSentry acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes. The Company has not disclosed the amount of revenue and earnings for sales of BioSentry products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the BioSentry acquisition, which are included in acquisition, restructuring and other expenses, net in the accompanying Consolidated Statements of Operations, were approximately $1.0 million in fiscal year 2019. The following table summarizes the preliminary and revised final purchase price allocated to the net assets acquired: (in thousands) Final allocation Inventory $ 50 Property, plant and equipment 10 Intangible assets: BioSentry trademark 2,500 BioSentry product technology 20,900 Customer relationships 2,600 Goodwill 13,740 Net assets acquired $ 39,800 The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of fiscal year 2019. The values assigned to the BioSentry trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademark and product technologies are deemed to have a fifteen The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over ten years.

Divestitures

Divestitures	12 Months Ended
	May 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
DIVESTITURES	DIVESTITURES Fluid Management On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the “Divestiture”) and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. (“Medline”) pursuant to an asset purchase agreement dated April 17, 2019 (the “Asset Purchase Agreement”). Total consideration received by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was $169.2 million in cash and resulted in a gain of $46.6 million after working capital adjustments of $0.6 million. The gain is recorded in discontinued operations. On June 3, 2019, a portion of the net proceeds were used to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business. Pursuant to a transition services agreement entered into and effective on the closing of the transaction, the Company will supply certain services to Medline. Medline will receive certain legal, human resource, tax, accounting and information technology services from the Company for a period generally not to exceed 24 months. As a result of the Divestiture, the results of operations from the Fluid Management business are reported in the accompanying consolidated statements of operations as “Income from discontinued operations, net of income tax” for the years ended May 31, 2019 and 2018. The following table summarizes the financial results of discontinued operations: Year ended May 31, (in thousands) 2019 2018 Net sales $ 88,850 $ 82,630 Cost of sales (exclusive of amortization) 52,978 49,611 Gross profit 35,872 33,019 Operating expenses Research and development 1,177 1,121 Sales and marketing 4,129 4,167 General and administrative 271 274 Amortization of intangibles 2,716 2,729 Total operating expenses 8,293 8,291 Operating income 27,579 24,728 Gain on divestiture 46,592 — Income from discontinued operations before income taxes 74,171 24,728 Income tax expense (1,685) (2,166) Income from discontinued operations $ 72,486 $ 22,562 In accordance with accounting principles generally accepted in the United States (“GAAP”), only expenses specifically identifiable and related to a business to be disposed may be allocated to discontinued operations. As such, the selling and marketing, research and development and general and administrative expenses recorded in discontinued operations include corporate costs incurred directly in support of the Fluid Management portfolio. The Company applied the “Intraperiod Tax Allocation” rules under ASC 740, which requires the allocation of an entity’s total annual income tax provision among continuing operations and, in the Company’s case, discontinued operations. Included in the $1.6 million income tax expense for fiscal year 2019 is $0.6 million tax expense related to the gain on the Divestiture. The taxes on the gain were calculated using various state statutory tax rates and are partially offset by the utilization of historical state net operating losses. There are no current federal taxes on the gain due to utilization of historical net operating losses which had a corresponding valuation allowance. The table below provides a reconciliation of the gain recorded on the sale of the Fluid Management business: (in thousands) Proceeds received from Divestiture $ 169,242 Working capital adjustment (612) Fluid Management assets: Inventories 11,029 Property, plant and equipment, net 16,624 Intangible assets, net 15,047 Goodwill 75,308 Total Fluid Management assets 118,008 Transaction costs for Divestiture (1) 4,030 Gain on sale of the Fluid Management business before income taxes $ 46,592 (1) Costs include advisory fees, legal fees and professional fees Proceeds from the sale of Fluid Management have been presented in the Consolidated Statements of Cash Flows under investing activities for the fiscal year ended May 31, 2019. Total operating and investing cash flows of discontinued operations for the fiscal year ended May 31, 2019 and 2018 are comprised of the following, which exclude the effect of income taxes: (in thousands) 2019 2018 Net cash provided by operating activities $ 2,245 $ 5,581 Net cash provided by investing activities 982 1,146

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	May 31, 2020
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue Recognition Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company has one primary revenue stream which is the sales of its products. Disaggregation of Revenue The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the year ended May 31, 2020 and for the year ended May 31, 2019: Year ended May 31, 2020 Year ended May 31, 2019 (in thousands) United States International Total United States International Total Net sales Vascular Interventions & Therapies $ 98,965 $ 13,741 $ 112,706 $ 106,767 $ 13,134 $ 119,901 Vascular Access 76,768 17,531 94,299 79,611 15,119 94,730 Oncology 32,247 24,905 57,152 30,579 25,424 56,003 Total $ 207,980 $ 56,177 $ 264,157 $ 216,957 $ 53,677 $ 270,634 Net Product Revenue The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distribution partners and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. Contracts and Performance Obligations The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Transaction Price and Allocation to Performance Obligations Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately. Revenue Recognition Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract. In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer. The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. Sales, value added, and other taxes collected on behalf of third parties are excluded from revenue. Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the year ended May 31, 2020, such product returns were not material. Contract Balances with Customers A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying consolidated balance sheets. The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers: (in thousands) May 31, 2020 May 31, 2019 Receivables $ 31,263 $ 43,577 Contract assets $ — $ — Contract liabilities $ 545 $ 681 During the years ended May 31, 2020 and 2019, the Company had additions to contract liabilities of $2.1 million and $0.6 million, respectively. This was offset by $2.2 million and $1.1 million in revenue that was recognized during the years ended May 31, 2020 and 2019, respectively. Costs to Obtain or Fulfill a Customer Contract Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	May 31, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows: • Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. The Company's financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities. The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities. The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurements using inputs considered as: (in thousands) Level 1 Level 2 Level 3 Fair Value at May 31, 2020 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 15,647 $ 15,647 Total Financial Liabilities $ — $ — $ 15,647 $ 15,647 Fair Value Measurements using inputs considered as: (in thousands) Level 1 Level 2 Level 3 Fair Value at May 31, 2019 Financial Liabilities Contingent consideration for acquisition earn out $ — $ — $ 13,486 $ 13,486 Total Financial Liabilities $ — $ — $ 13,486 $ 13,486 There were no transfers in and out of Level 1, 2 and 3 measurements for the years ended May 31, 2020 and 2019. The table below presents the changes in fair value components of Level 3 instruments in the year ended May 31, 2020: Financial Liabilities (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance at May 31, 2019 $ 13,486 Contingent consideration liability recorded as a result of the acquisition (Note 2) 14,900 Change in present value of contingent consideration (1) (11,531) Contingent consideration payments (1,208) Balance at May 31, 2020 $ 15,647 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. During fiscal year 2020, the Company revised the sales projections for RadiaDyne products as a result of reviews performed by executive management. The adjustments to the sales projections over the contractual earn-out period resulted in a $9.2 million reduction in the fair value of the contingent liability. It was also determined that one of the technical milestones would not be achieved, which resulted in an additional reduction in the liability of $2.7 million. The table below presents the changes in fair value components of Level 3 instruments in the year ended May 31, 2019: Financial Assets Financial Liabilities (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance at May 31, 2018 $ 1,317 $ 3,261 Contingent consideration liabilities recorded as a result of the acquisitions (Note 2) — 25,101 Change in fair value of contingent consideration (1) — (6,776) Fair market value adjustments 33 — Proceeds from sale of marketable securities (1,350) — Contingent consideration payments — (8,100) Balance at May 31, 2019 $ — $ 13,486 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. In the fourth quarter of fiscal year 2019, the Company revised the sales projections for RadiaDyne products as a result of reviews performed by executive management. The adjustments to the sales projections over the contractual earn-out period resulted in a $8.4 million reduction in the fair value of the contingent liability. Contingent Liability for Acquisition Earn Outs Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the consolidated statements of income. The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May 31, 2020: (in thousands) Fair Value Valuation Technique Unobservable Input Range Revenue based payments $ 14,811 Discounted cash flow Discount rate 5% Probability of payment 66% - 100% Projected fiscal year of payment 2024 - 2025 Technical milestones 836 Estimated probability Estimated probability 90% Projected year of payment 2021 $ 15,647 At May 31, 2020, the amount of undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is approximately $21.0 million. The milestones, including revenue projections and technical milestones, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2021 to 2025 in order for the associated consideration to be paid. Items Measured at Fair Value on a Nonrecurring Basis The Company recorded a goodwill impairment charge of $158.6 million as of May 31, 2020 to write down the carrying value of the reporting unit to fair value using Level 3 inputs. There were no other items measured at fair value on a nonrecurring basis during the year ended May 31, 2020.

Inventories

Inventories	12 Months Ended
	May 31, 2020
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following: (in thousands) May 31, 2020 May 31, 2019 Raw materials $ 23,308 $ 16,045 Work in process 8,318 6,786 Finished goods 28,279 17,240 Total $ 59,905 $ 40,071

Prepaid Expenses and Other

Prepaid Expenses and Other	12 Months Ended
	May 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER	PREPAID EXPENSES AND OTHER Prepaid expenses and other consisted of the following: (in thousands) May 31, 2020 May 31, 2019 TSA receivable $ 2,911 $ — Software licenses 1,002 1,131 License fees 203 145 Trade shows 296 213 Rent 246 199 Other prepaid taxes 414 112 Other 2,238 2,203 Total $ 7,310 $ 4,003

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	May 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment are summarized as follows: (in thousands) May 31, 2020 May 31, 2019 Building and building improvements $ 27,119 $ 24,535 Machinery and equipment 13,602 14,029 Computer software and equipment 24,730 24,980 Construction in progress 3,050 1,239 68,501 64,783 Less accumulated depreciation and amortization (40,661) (41,608) 27,840 23,175 Land and land improvements 472 1,083 $ 28,312 $ 24,258

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	May 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The Company's annual testing for impairment of goodwill was completed as of December 31, 2019. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value as of December 31, 2019. As a result of the current economic environment and the impact that the COVID-19 global pandemic has had on the global capital markets, the Company’s market capitalization was below its reporting unit’s carry value as of February 29, 2020; however, it was concluded that this decline in market capitalization was temporary. In the fourth quarter of fiscal year 2020, the Company concluded that the sustained decline in its market capitalization represented an impairment indicator that required the Company to perform an interim test for goodwill impairment as of May 31, 2020. To determine the fair value of the single reporting unit as of May 31, 2020, the Company utilized a weighting of fair values derived from the income approach and the market approach. The income approach is based on the projected cash flows that are discounted to their present value using discount rates that consider the timing and risk of the forecasted cash flows. Fair value is estimated using internally developed forecasts and assumptions. The discount rate used is the average estimated value of a market participant’s cost of capital and debt, derived using customary market metrics. Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates. The market approach estimates fair values based on the determination of appropriate publicly traded market comparison companies and market multiples of revenue and earnings derived from those companies with similar operating and investment characteristics as the Company being valued. Finally, the Company compared and reconciled the Company’s overall fair value to its market capitalization in order to assess the reasonableness of the calculated fair values of the reporting unit. Based on the results of this evaluation, the Company recorded a goodwill impairment charge of $158.6 million as of May 31, 2020 to write down the carrying value of the reporting unit to fair value. The impairment loss is disclosed separately on the face of the accompanying consolidated statements of operations. The assumptions related to the development of fair value could deviate materially from actual results and forecasts used to support the assets carrying value and may change in the future, which could result in impairment charges that would adversely affect financial results of operations. The changes in the carrying amount of goodwill for the year ended May 31, 2020 were as follows: (in thousands) Goodwill balance at May 31, 2019 $ 347,666 Additions for Eximo acquisition (Note 2) 11,427 Goodwill impairment (158,578) Goodwill balance at May 31, 2020 $ 200,515 Definite Lived Intangible Assets Definite lived intangible assets consist primarily of product technologies and customer relationships and are amortized over their estimated useful lives, which range between two Intangible assets consisted of the following: May 31, 2020 (in thousands) Gross carrying Accumulated Net carrying Product technologies $ 251,569 $ (88,547) $ 163,022 Customer relationships 60,160 (30,018) 30,142 Trademarks 10,150 (6,691) 3,459 Licenses 6,087 (5,574) 513 $ 327,966 $ (130,830) $ 197,136 May 31, 2019 (in thousands) Gross carrying Accumulated Net carrying Product technologies $ 182,971 $ (75,412) $ 107,559 Customer relationships 60,166 (25,950) 34,216 Trademarks 9,300 (6,404) 2,896 Licenses 5,752 (5,036) 716 $ 258,189 $ (112,802) $ 145,387 Annual amortization of these intangible assets is expected to approximate the following amounts for each of the next five fiscal years: (in thousands) 2021 $ 18,604 2022 18,001 2023 17,941 2024 16,369 2024 17,221 2025 and thereafter 109,000 $ 197,136

Income Taxes

Income Taxes	12 Months Ended
	May 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXESThe components of loss from continuing operations before income tax benefit are as follows: Year ended May 31, (in thousands) 2020 2019 2018 Loss from continuing operations before tax expense: U.S. $ (166,984) $ (15,593) $ (18,454) Non-U.S. (1,151) 891 1,191 $ (168,135) $ (14,702) $ (17,263) Income tax benefit is comprised of the following: Year ended May 31, (in thousands) 2020 2019 2018 Current Federal $ — $ — $ (148) State and local 96 128 152 Non U.S. 124 289 73 220 417 77 Deferred (1,568) (3,973) (11,113) Income tax benefit $ (1,348) $ (3,556) $ (11,036) Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows: (in thousands) May 31, 2020 May 31, 2019 Deferred tax assets Net operating loss carryforward $ 26,697 $ 18,955 Stock-based compensation 2,923 3,395 Federal and state R&D tax credit carryforward 5,412 4,259 Inventories 1,071 971 Expenses incurred not currently deductible 1,927 1,337 Accrued liabilities 95 139 Gross deferred tax asset 38,125 29,056 Deferred tax liabilities Depreciation and amortization 49,023 31,878 49,023 31,878 Valuation allowance (13,114) (11,688) Net deferred tax liability $ (24,012) $ (14,510) The net deferred tax liability in the U.S. as of May 31, 2020 and 2019 principally relates to tax amortization of intangibles that have an indefinite reversal period for book purposes, also known as a “naked credit deferred tax liability”, that cannot be considered as a source of income to recover the deferred tax asset. In addition, during the fiscal year ended May 31, 2020 a net deferred tax liability of $11.0 million was recorded in purchase accounting related to the stock acquisition of Eximo Medical Ltd. primarily related to book intangibles offset by tax net operating losses. The Company's U.S. Federal net operating loss carryforwards as of May 31, 2020 after considering IRC Section 382 limitations are $112.3 million. The expiration of the Federal net operating loss carryforwards are as follows: $8.6 million between 2022 and 2023, $79.4 million between 2028 and 2037 and $24.3 million indefinitely. The Company's state net operating loss carryforwards as of May 31, 2020 after considering remaining IRC Section 382 limitations are $9.3 million which expire in various years from 2020 to 2040. The Company has Israel tax net operating losses of $11.0 million that can be carried forward indefinitely. Beginning in 2018, except for GILTI, the Company will no longer record United States federal income tax on its share of the income of its foreign subsidiaries, nor will it record a benefit for foreign tax credits related to that income. Upon distribution of these earnings in the form of dividends or otherwise, the Company would be subject to withholding taxes payable, where applicable, to foreign countries, but would have no further federal income tax liability. The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal year 2016, except the naked credit deferred tax liability. Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of May 31, 2020. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations. The Company's consolidated income tax expense has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to the Company's income before income taxes for the following reasons: Year ended May 31, (in thousands) 2020 2019 2018 Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 28.6%, respectively $ (35,308) $ (3,087) $ (4,941) State income taxes, net of Federal tax benefit (40) (177) 120 Impact of Non-U.S. operations (81) 76 (288) Research and development tax credit (1,152) (936) (951) Impact of tax reform — — 12,860 Meals and entertainment 171 190 242 Goodwill impairment 33,301 — — Non-deductible interest on contingent payments 99 — — Non-taxable gain on revaluation of contingent consideration liability (118) — — Change in valuation allowance 1,426 175 (18,526) Effect of elimination of stock compensation APIC pool 162 — — Other 192 203 448 Income tax benefit $ (1,348) $ (3,556) $ (11,036) During fiscal year 2020, the Company recorded a goodwill impairment of $158.6 million. The Company has made the tax accounting policy election to first allocate the impairment to the Company’s nondeductible goodwill based on the Company’s pre-impairment nondeductible goodwill balance. The following table provides a reconciliation of the beginning and ending amount of unrecognized tax benefits: Year ended May 31, (in thousands) 2020 2019 2018 Unrecognized tax benefits balance at June 1 $ 464 $ 464 $ 899 Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform — — (287) Decrease due to lapse in statute of limitations — — (148) Unrecognized tax benefits balance at May 31 $ 464 $ 464 $ 464 The table above includes unrecognized tax benefits associated with the calculation of limitations placed on the utilization of tax attributes related to an acquired company. If recognized, $0.5 million would result in adjustments to other tax accounts. The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. There are no accrued interest and penalties recognized in the consolidated balance sheet as of May 31, 2020 and May 31, 2019. The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business the Company is subject to examination by taxing authorities throughout the world. Fiscal years 2017 through 2019 remain open to examination by the various tax authorities. The Company does not anticipate that the amount of unrecognized tax benefits will significantly change in the next twelve months.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	May 31, 2020
Payables and Accruals [Abstract]
ACCRUED LIABILITIES	ACCRUED LIABILITIES Accrued liabilities consist of the following: (in thousands) May 31, 2020 May 31, 2019 Payroll and related expenses $ 13,059 $ 14,987 Royalties 2,392 2,088 Accrued severance 794 504 Sales and franchise taxes 634 807 Outside services 2,222 3,514 Litigation matters (Note 17) — 2,700 Indemnification holdback 5,000 4,807 Other 5,279 8,931 Total $ 29,380 $ 38,338

Long Term Debt

Long Term Debt	12 Months Ended
	May 31, 2020
Debt Disclosure [Abstract]
Long Term Debt	LONG-TERM DEBT On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and Bank of America, N.A. and KeyBank National Association, as co-syndication agents. The Credit Agreement provides for a $125.0 million secured revolving credit facility (the “Revolving Facility”), which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million. The proceeds may be used to refinance certain existing indebtedness of the Company and its subsidiaries, to finance the working capital needs, and for general corporate purposes (including permitted acquisitions), of the Company and its subsidiaries. The Credit Agreement has a five year maturity. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. After default, the interest rate may be increased by 2.0%. The facility will also carry a commitment fee of 0.20% to 0.25% per annum on the unused portion. The Company's obligations under the Revolving Facility are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: • Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00). • Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00. * The definitions of consolidated total indebtedness and consolidated EBITDA are maintained in the credit agreement included as an exhibit to Form 8-k filed on June 6, 2019. As of May 31, 2020 there was $40.0 million outstanding on the Revolving Facility. As of May 31, 2020 and May 31, 2019, the carrying value of long-term debt approximated its fair market value. The interest rate on the Revolving Facility at May 31, 2020 was 1.43%.

Retirement Plans

Retirement Plans	12 Months Ended
	May 31, 2020
Retirement Benefits [Abstract]
RETIREMENT PLANS	RETIREMENT PLANSThe Company has a 401(k) plan under which eligible employees can defer a portion of their compensation, part of which is matched by the Company. Matching contributions were $3.2 million, $3.6 million and $3.9 million in 2020, 2019 and 2018, respectively. There are also various immaterial foreign retirement plans.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	May 31, 2020
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Capitalization On October 29, 2014, the Board of Directors approved the Amended and Restated Certificate of Incorporation (the “Amended Certificate”). Under the Amended Certificate, the authorized capital stock is 80,000,000 shares, consisting of 75,000,000 shares of common stock, par value $.01 per share and 5,000,000 shares of preferred stock, par value $.01 per share. The holders of common stock are entitled to one vote for each share held. Subject to preferences applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably dividends, if any, as may be declared by the Board of Directors out of funds legally available for dividend payments. If the Company liquidates, dissolves, or winds up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no pre-emptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future. The Board of Directors has the authority to (i) issue the undesignated preferred stock in one or more series, (ii) determine the powers, preferences and rights and the qualifications, limitations or restrictions granted to or imposed upon any wholly un-issued series of undesignated preferred stock and (iii) fix the number of shares constituting any series and the designation of the series, without any further vote or action by the Company's stockholders. Stock Options 2004 Stock and Incentive Award Plan The 2004 Stock and Incentive Award Plan (the “2004 Plan”) provides for the grant of incentive options to employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to employees, directors and other service providers. A total of 7,750,000 shares of common stock have been reserved for issuance under the 2004 Plan, of which up to 800,000 shares may be issued upon the exercise of incentive stock options. The Compensation Committee of the Board of Directors administers the 2004 Plan. The Committee determines vesting terms and the exercise price of options granted under the 2004 Plan, but for all incentive stock options the exercise price must at least be equal to the fair market value of common stock on the date of grant. The term of an incentive stock option may not exceed ten years. On October 25, 2016, the Company amended the 2004 Stock and Incentive Award Plan to increase the shares of common stock reserved for issuance by 250,000 shares. On October 10, 2018, the Company amended the 2004 Stock and Incentive Award Plan to increase the shares of common stock reserved for issuance by 750,000 shares. As of May 31, 2020, there remained approximately 1.6 million shares available for granting under the 2004 Plan. The following table summarizes information about stock option activity for the fiscal year ended May 31, 2020: Shares Weighted average exercise price Weighted average remaining contractual life Aggregate intrinsic value (in thousands) Outstanding at beginning of year - June 1, 2019 1,760,313 $ 16.54 Granted 539,946 $ 18.92 Exercised (61,100) $ 12.67 Forfeited (300,406) $ 17.81 Expired Outstanding at end of year - May 31, 2020 1,938,753 $ 16.89 6.00 $ — Options exercisable at year-end 1,004,531 $ 15.63 3.70 $ — Options expected to vest in future periods 934,222 $ 18.25 8.40 $ — Stock options are granted at exercise prices equal to the quoted market price of common stock at the date of the grant. Options vest 25% per year over four years for employees. Grants to directors vest 33.33% per year over three years. Stock options granted prior to May 1, 2007 and after June 1, 2017 expire on the tenth anniversary of the grant date. Stock options granted between May 1, 2007 through May 31, 2017 expire on the seventh anniversary of the grant date. The Company measures the fair value of each stock option grant at the date of grant using a Black-Scholes option pricing model. The weighted average grant-date fair value of options granted during the years ended May 31, 2020, 2019 and 2018 was $5.46, $6.53, and $4.95, respectively. The following assumptions were used in arriving at the fair value of options granted during 2020, 2019 and 2018, respectively: risk-free interest rates of 1.63%, 2.78% and 2.08%; expected volatility of 31%, 31%, and 30%; and expected lives of 4.91 years, 4.79 years, and 4.72 years. The Company does not declare dividends therefore a dividend yield of zero was used for the years ended May 31, 2020, 2019 and 2018. Risk-free interest rates reflect the yield on zero-coupon U.S. Treasury bonds whose maturity period equals the expected term of the option. Expected volatilities are based on the historical volatility of the Company's stock. The expected option lives are based on historical experience of employee exercise behavior. The total intrinsic value of options exercised during the years ended May 31, 2020, 2019 and 2018 was $0.5 million, $1.4 million, and $0.7 million, respectively. As of May 31, 2020, there was $4.0 million of total unrecognized compensation cost related to non-vested options, which is expected to be recognized over a weighted average period of 3 years. Cash received from option exercises during 2020, 2019 and 2018 was $0.6 million, $1.5 million and $2 million, respectively. Due to the valuation allowance there was no tax benefit realized from stock option exercises during the years ended May 31, 2020, 2019 and 2018. Performance Share and Restricted Stock Unit Awards The Company grants restricted stock units to certain employees under the 2004 Plan which give the recipients the right to receive shares of Company stock upon vesting. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. Restricted stock unit awards granted to directors vest over one The following table summarizes information about restricted stock unit activity for the year ended May 31, 2020: Restricted Stock Units Weighted Average Grant-Date Fair Value Non-vested at beginning of year, June 1, 2019 430,936 $ 18.60 Granted 278,064 $ 20.35 Vested (197,985) $ 19.75 Canceled (46,094) $ 19.68 Non-vested at end of year, May 31, 2020 464,921 $ 19.65 The fair value of each restricted stock unit is the market price of Company stock on the date of grant. The weighted average grant date fair value of restricted stock units granted during the years ended May 31, 2020, 2019 and 2018 was $20.35, $20.87 and $16.60, respectively. The total intrinsic value of restricted stock units (meaning the fair value of the units on the date of vest) vesting during the years ended May 31, 2020, 2019 and 2018 was $3.9 million, $4.6 million, and $2.7 million, respectively. As of May 31, 2020, there was $5.7 million of total unrecognized compensation cost related to non-vested restricted stock awards, which is expected to be recognized over a weighted average period of 3 years. The Company grants performance share awards to certain employees under the 2004 Plan which gives the recipients the right to receive shares of Company stock if certain criteria is met. The following table summarizes information about performance unit award activity for the year ended May 31, 2020: Performance Unit Awards Weighted Average Grant-Date Fair Value Non-vested at beginning of year, June 1, 2019 538,605 $ 21.55 Granted 111,594 $ 14.06 Vested (235,580) $ 21.68 Canceled (141,498) $ 20.86 Non-vested at end of year, May 31, 2020 273,121 $ 22.07 During fiscal year 2020, the Company granted performance unit awards. Performance unit awards subject to vesting are based on the Company's level of attainment of the performance targets which are set for each of the three performance years along with continued employment of the grantee. At the end of the three year period, the vested shares are subject to modification based on the Company’s TSR targets relative to the percentage appreciation of a specified index of companies for the respective three-year period. During fiscal years 2019 and 2018, the Company granted performance unit awards that include a three-year market condition. Vesting of the performance unit awards is based on the Company's level of attainment of specified TSR targets relative to the percentage appreciation of a specified index of companies for the respective three-year periods. It is also subject to the continued employment of the grantees. In order to estimate the fair value of such awards, a Monte Carlo Simulation valuation model on the date of the grant was used. For the years ended May 31, 2020, 2019 and 2018, the weighted average grant date fair market value for new grants was $14.06, $28.62 and $23.83, respectively. Compensation cost is recognized over the performance period which is typically three Compensation Expense The following tables represents the break out of share-based compensation included in the Company's consolidated statement of operations: Year ended May 31, (in thousands) 2020 2019 2018 Cost of sales $ 655 $ 461 $ 119 Research and development 971 724 554 Sales and marketing 1,665 1,952 1,778 General and administrative 4,302 6,112 5,461 $ 7,593 $ 9,249 $ 7,912 The income tax benefit on the compensation expense recognized for all share-based compensation arrangements was $1.7 million, $2.1 million and $1.8 million for the years ended May 31, 2020, 2019 and 2018, respectively. The income tax benefit for 2020, 2019 and 2018 are negated by the full valuation allowance recorded against the deferred tax assets. Employee Stock Purchase Plan The Employee Stock Purchase Plan (the “Stock Purchase Plan”) provides a means by which employees (the “participants”) are given an opportunity to purchase the Company's common stock through payroll deductions. A total of 3,500,000 shares of common stock have been reserved for issuance under the Stock Purchase Plan. Shares are offered through two purchase periods, each with duration of approximately 6 months, commencing on the first business day of the first and third fiscal quarters. An employee is eligible to participate in an offering period if, on the first day of an offering period, he or she has been employed in a full-time capacity for at least six months, with a customary working schedule of 20 or more hours per week and more than five months in a calendar year. Employees who own stock possessing 5% or more of the total combined voting power or value of all classes of stock are not eligible to participate in the Stock Purchase Plan. The purchase price of the shares of common stock acquired on each purchase date will be the lower of (i) 85% of the fair market value of a share of common stock on the first day of the offering period or (ii) 85% of the fair market value of a share of common stock on the last day of the purchase period, subject to adjustments made by the Board of Directors. The Stock Purchase Plan is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. During the years ended May 31, 2017 and 2019, an additional 500,000 and 1,000,000 shares of the Company's common stock, respectively, were reserved for issuance under the Stock Purchase Plan. The Company uses the Black-Scholes option-pricing model to calculate the purchase date fair value of the shares issued under the Stock Purchase Plan and recognize expense related to shares purchased ratably over the offering period. During the years ended May 31, 2020, 2019 and 2018, 100,567, 72,863 and 89,943 shares, respectively, were issued at an average price of $12.11, $16.08 and $14.03, respectively, under the Stock Purchase Plan. As of May 31, 2020, 2.1 million shares remained available for future purchases under the Stock Purchase Plan.

Earnings Per Share

Earnings Per Share	12 Months Ended
	May 31, 2020
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE Basic earnings per share are based on the weighted average number of common shares outstanding. In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive. The following table reconciles basic to diluted weighted average shares outstanding for the years ended May 31, 2020, 2019 and 2018: Year ended May 31, 2020 2019 2018 Basic 37,961,224 37,484,573 37,074,797 Effect of dilutive securities — — — Diluted 37,961,224 37,484,573 37,074,797 Securities excluded as their inclusion would be anti-dilutive 2,581,006 2,200,318 1,077,256

Leases Leases

Leases Leases	12 Months Ended
	May 31, 2020
Leases [Abstract]
Leases	LEASES Adoption of ASU No. 2016-02, Leases (Topic 842) On June 1, 2019, the Company adopted ASU No. 2016-02 The Company elected the three practical expedients that permit an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets. The adoption of this standard resulted in the recording of an additional lease asset and lease liability of approximately $5.6 million. The standard did not have a material impact on the Company's Consolidated Statement of Operations, Stockholders Equity or Cash Flows. Leases The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The following table presents supplemental balance sheet information related to leases: (in thousands) Balance Sheet Location May 31, 2020 Assets Operating lease ROU asset Other assets $ 10,146 Liabilities Current operating lease liabilities Other current liabilities 2,077 Non-current operating lease liabilities Other long-term liabilities 8,345 Total lease liabilities $ 10,422 The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate: May 31, 2020 Weighted average remaining term (in years) 5.00 Weighted average discount rate 4.2 % The following table presents the maturities of the lease liabilities: (in thousands) May 31, 2020 2021 $ 2,466 2022 2,357 2023 2,403 2024 1,864 2025 1,259 2026 and thereafter 1,188 Total lease payments $ 11,537 Less: Imputed Interest 1,115 Total lease obligations $ 10,422 Less: Current portion of lease obligations 2,077 Long-term lease obligations $ 8,345 Included in the total lease obligations is a 7-year building operating lease with undiscounted payment obligations of $6.4 million that commenced during the third quarter of fiscal year 2020 and a 5-year building operating lease with undiscounted payment obligations of $1.5 million that commenced during the fourth quarter of fiscal year 2020. During the year ended May 31, 2020, the Company recognized $3.4 million of operating lease expense which includes immaterial short-term leases. Rent expense prior to adoption of ASC 842 amounted to $2.5 million and $2.8 million for the years ended May 31, 2019 and 2018, respectively. As of May 31, 2020, the expenses on the Consolidated Statement of Operations were classified as follows: (in thousands) May 31, 2020 Cost of sales $ 1,138 Research and development 583 Sales and marketing 397 General and administrative 1,233 $ 3,351 The following table presents supplemental cash flow and other information related to leases for the year ended: (in thousands) May 31, 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 2,372 ROU assets obtained in exchange for lease liabilities Operating leases 6,918 Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows: (in thousands) May 31, 2019 2020 $ 2,920 2021 2,338 2022 2,133 2023 2,131 2024 and thereafter 3,227 Total lease payments $ 12,749

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	May 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Other Commitments and Contingencies The following table summarizes the Company's other future commitments and contingencies as of May 31, 2020: (in thousands) Total 2021 2022 2023 2024 2025 and thereafter Purchase obligations (1) $ 553 $ 553 $ — $ — $ — $ — Royalties (2) 51,500 3,800 3,800 3,800 3,800 36,300 $ 52,053 $ 4,353 $ 3,800 $ 3,800 $ 3,800 $ 36,300 (1) The non-cancelable inventory purchase obligations are not reflected on the consolidated balance sheets under accounting principles generally accepted in the United States of America. (2) These are future minimum royalty payments. Legal Proceedings The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation. C.R. Bard, Inc. v. AngioDynamics, Inc. On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard’s complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: For US Patent No. 7,785,302, the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. For U.S. Patent No. 7,959,615 the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third, for U.S. Patent No. 7,947,022 the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the ‘302 and ‘615 appeals. The PTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the ‘302 and ‘022 decisions. Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company Cross-Appealed for the ‘302 and the ‘615 reexams. MedComp also filed an Amicus Brief in support of the Company on November 22, 2017. Meanwhile, on July 12, 2017 Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. (“BPV”) which was added as co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action. An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the ‘615 patent were invalid, but that claims 6-7 of the 615 patent and claims 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings. The Federal Circuit also reversed the PTAB’s claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication. On January 28, 2019, on remand, the USPTO reversed the rejections of the ‘302 claims 1-10, ‘022 claims 1-20 and ‘615 claims 8-9. The USPTO has since issued Inter Partes Reexamination Certificates for the ‘302 Patent for the ‘022 patent and for the ‘615 patent. The Company thereafter filed a Motion to Unstay the Utah Case and that motion was granted. On November 4, 2019 the Court held a joint Status Conference among the Company’s Utah Action and two other cases filed by Bard on the same patents against MedComp and Smiths. The Court set a schedule for defendant's Motions to Dismiss or Transfer. The Company filed its motion on November 25, 2019; and Bard filed a responsive brief and a motion for venue discovery on December 9, 2019. The Company filed a responsive brief on December 16, 2019 and Bard filed a reply on December 23, 2019. On February 27, 2020, the Court referred all non-dispositive motions to the presiding Magistrate and on March 3, 2020 the Court granted Bard’s Motion for Venue Discovery and denied the Company’s transfer motion without prejudice to re-filing after completion of the venue discovery, but no later than June 30, 2020. The parties have since engaged in venue discovery and AngioDynamics re-filed its Motion to Dismiss or Transfer on June 30, 2020. Bard filed an opposition brief on July 28, 2020, and the Company’s Reply is due 14 days thereafter. The Company believes these claims are without merit and intends to defend them vigorously. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the “Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court. On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions. On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation (by Magistrate-Judge Fallon) was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019. On day four of the jury trial, at the close of C.R. Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law under rule 50(a) as well as its motions for summary judgement on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company’s favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company’s fee Motion and the Company’s equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard’s opening brief was filed on September 27, 2019; the Company's answering brief was filed on January 15, 2020; and Bard’s reply brief was filed on March 4, 2020. A hearing date was held on June 1, 2020, and the Company is currently awaiting a decision from the Federal Circuit . The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. AngioDynamics, Inc. v. C.R. Bard, Inc. On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”). In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs. The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs. The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety. Discovery is largely complete, summary judgment will be fully briefed by September 11, 2020, and the case will subsequently proceed to trial thereafter. Merz North America Settlement

Segments and Geographic Informa

Segments and Geographic Information	12 Months Ended
	May 31, 2020
Segment Reporting [Abstract]
SEGMENTS AND GEOGRAPHIC INFORMATION	SEGMENTS AND GEOGRAPHIC INFORMATION Segment information The Company considers its business to be a single segment entity related to the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. The Company's chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting in to the CEO include those responsible for operations and supply chain management, research and development, sales, franchise marketing and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources. Total sales by product category are summarized below: Year ended May 31, (in thousands) 2020 2019 2018 Net sales by Product Category Vascular Interventions & Therapies $ 112,706 $ 119,901 $ 119,704 Vascular Access 94,299 94,730 92,760 Oncology/Surgery 57,152 56,003 49,191 Total $ 264,157 $ 270,634 $ 261,655 Geographic information Total sales for geographic areas are summarized below: Year ended May 31, (in thousands) 2020 2019 2018 Net sales by Geography United States $ 207,980 $ 216,957 $ 213,727 International 56,177 53,677 47,928 Total $ 264,157 $ 270,634 $ 261,655

Acquisition, Restructuring and

Acquisition, Restructuring and Other Items, net	12 Months Ended
	May 31, 2020
Restructuring and Related Activities [Abstract]
ACQUISITION, RESTRUCTURING AND OTHER ITEMS, NET	ACQUISITION, RESTRUCTURING AND OTHER ITEMS, NET Acquisition, restructuring and other items, net consisted of: Year ended May 31, (in thousands) 2020 2019 2018 Legal (1) $ 2,666 $ 7,802 $ 8,407 Mergers and acquisitions (2) 782 4,030 1,660 Transition service agreement (3) (1,799) — — Divestiture (4) 2,809 — — Intangible and other asset impairment — 1,704 — Restructuring 26 289 4,674 Other 1,530 1,302 691 Total $ 6,014 $ 15,127 $ 15,432 (1) Legal expenses related to litigation that is outside the normal course of business. (2) Mergers and acquisitions expenses related to investment banking, legal and due diligence. (3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business. (4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY. Included in legal for fiscal years 2020 and 2019 are settlements received for the Biolitec litigation of $0.5 million and $3.4 million, respectively. The settlement received offsets legal expenses paid related to the settlement proceedings. In addition, the $2.5 million accrual for the settlement of the Merz contract termination is included in legal expenses for fiscal year 2019. Restructuring The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations. Operational Consolidation On February 1, 2017, the Company announced to employees an operational consolidation plan (the “plan”) to consolidate manufacturing facilities in Manchester, GA and Denmead, UK into the Glens Falls and Queensbury, NY facilities. This plan will streamline and optimize the manufacturing functions into one centralized location increasing the utilization of the Glens Falls and Queensbury facilities, optimizing inventory and reducing cost of goods sold through savings in overhead expenses and direct labor. The restructuring activities associated with the plan were completed in the fourth quarter of fiscal year 2018 with immaterial validation and regulatory costs incurred in fiscal year 2019. The Company recorded restructuring charges related to the plan during the year ended May 31, 2020, 2019 and 2018 of $0.0 million, $0.3 million and $4.7 million, respectively. Total restructuring charges recorded as part of the plan were $6.3 million. Termination benefits were only earned if an employee stays until their termination date; therefore, the expenses related to termination benefits were recorded ratably over the service period. The following table presents a rollforward of the restructuring reserve for the years ended May 31, 2020, 2019 and 2018: Contract Termination Plant Regulatory Cancellation Other (in thousands) Benefits Consolidation Filings Costs Costs Total Balance at May 31, 2017 $ 851 $ 111 $ — $ — $ — $ 962 Charges 1,440 2,892 68 200 74 4,674 Non-cash adjustments — (276) — — — (276) Cash payments (1,453) (2,706) (56) — (74) (4,289) Balance at May 31, 2018 $ 838 $ 21 $ 12 $ 200 $ — $ 1,071 Charges — 244 44 — — 288 Non-cash adjustments — — — (9) — (9) Cash payments (838) (265) (44) (191) — (1,338) Balance at May 31, 2019 $ — $ — $ 12 $ — $ — $ 12 Charges — — 26 — — 26 Cash payments — — (38) — — (38) Balance at May 31, 2020 $ — $ — $ — $ — $ — $ —

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	May 31, 2020
Equity [Abstract]
ACCUMULATED OTHER COMPREHESIVE INCOME (LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows for fiscal years 2020 and 2019: (in thousands) Foreign currency translation gain (loss) Unrealized gain (loss) on marketable securities Total Balance at May 31, 2018 $ (1,035) $ 83 $ (952) Other comprehensive income before reclassifications, net of tax (317) 33 (284) Amounts reclassified from accumulated other comprehensive income — (116) (116) Net other comprehensive income $ (317) $ (83) $ (400) Balance at May 31, 2019 $ (1,352) $ — $ (1,352) Other comprehensive income (loss) before reclassifications, net of tax 11 — 11 Net other comprehensive loss $ 11 $ — $ 11 Balance at May 31, 2020 $ (1,341) $ — $ (1,341)

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	May 31, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
VALUATION AND QUALIFYING ACCOUNTS	(in thousands) SCHEDULE II -VALUATION AND QUALIFYING ACCOUNTS Description Balance at Beginning of Year Additions - Charged to costs and expenses Deductions Balance at End of Period Year Ended May 31, 2018 Allowance for deferred tax asset $ 48,348 $ — $ (21,741) $ 26,607 Allowance for sales returns and doubtful accounts $ 2,945 $ 608 $ (1,087) $ 2,466 Year Ended May 31, 2019 Allowance for deferred tax asset $ 26,607 $ — $ (14,919) $ 11,688 Allowance for sales returns and doubtful accounts $ 2,466 $ 393 $ (953) $ 1,906 Year Ended May 31, 2020 Allowance for deferred tax asset $ 11,688 $ 1,426 $ — $ 13,114 Allowance for sales returns and doubtful accounts $ 1,906 $ 1,218 $ (974) $ 2,150

Basis of Presentation, Busine_2

Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	May 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Description of Business	Basis of Presentation and Description of Business The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the “Company”). The Company designs, manufactures and sells a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and in oncology and surgical settings. The devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use. On May 31, 2019, the Company completed the sale of the Fluid Management business and all of the assets used primarily in connection with the Fluid Management business (Note 3). As the disposal of this business represents a strategic shift with a major effect on the Company's operations, for all periods presented in the Consolidated Statements of Operations and Comprehensive Income, all sales, costs, expenses, gains and income taxes attributable to Fluid Management have been reported under the captions, “Income from Discontinued Operations, Net of Income Tax.” Cash flows used in or provided by Fluid Management have been reported in the Consolidated Statements of Cash Flows under operating and investing activities. Accounting Principles The consolidated financial statements and accompanying notes have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Principles of Consolidation The consolidated financial statements include the accounts of AngioDynamics and its subsidiaries (all of which are wholly owned). All intercompany balances and transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all unrestricted highly liquid investments with an initial maturity of less than three months at the date of purchase to be cash equivalents. The Company maintains cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation.
Fair Value Instruments	Fair Value Instruments The carrying amount of the Company's cash and cash equivalents, accounts receivable, accounts payable and long-term debt approximates fair value due to the short-term nature or market interest rates of these items. The Company bases the fair value of short-term investments on quoted market prices or other relevant information generated by market transactions involving identical or comparable assets. The Company measures and records derivative financial instruments at fair value. See Note 5 for further discussion of financial instruments that are carried at fair value on a recurring and nonrecurring basis.
Accounts Receivable	Accounts Receivable Accounts receivable, principally trade receivables, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for estimated sales returns and doubtful accounts. The Company performs ongoing credit evaluations of customers and adjusts credit limits based upon payment history and the customer’s current creditworthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations
Inventories	Inventories Inventories are stated at the lower of cost (using the first-in, first-out method) or market. Appropriate consideration is given to deterioration, obsolescence, expiring and other factors in evaluating net realizable value.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Refer below for useful lives by category: Estimated useful lives Building and building improvements 39 years Machinery and equipment 5 to 8 years Computer software and equipment 3 to 5 years The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Intangible assets other than goodwill, indefinite lived intangible assets and in process research and development ("IP R&D") are amortized over their estimated useful lives, which range between two Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition. For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the carrying value of the assets and liabilities of that reporting unit. The determination of reporting units also requires management judgment. The Company considers whether a reporting unit exists within a reportable segment based on the availability of discrete financial information. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. If the carrying value of the reporting unit exceeds the fair value of the reporting unit, the carrying value is reduced to its fair value through an adjustment to the goodwill balance, resulting in an impairment charge. As detailed in Note 9, "Goodwill and Intangible Assets," the Company recorded a goodwill impairment loss of $158.6 million for the year ended May 31, 2020 as the fair value of the reporting unit was less than its carrying value.
Contingent Consideration	Contingent Consideration The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods and reflective of the risk associated with the estimated cash flow streams. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services. See Note 4, “Revenue from Contracts with Customers” for further discussion on revenue.
Research and Development	Research and Development Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred.
Income Taxes	Income Taxes The Company calculates income tax expense for each jurisdiction in which it operates. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. The Company periodically evaluates deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on the Company's ability to generate future taxable income and capital gains. Where it is more-likely-than-not these will not be recovered, the Company estimates a valuation allowance and records a corresponding additional tax expense in the consolidated statement of operations. The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return utilizing a two-step approach. The Company first determines if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is that the Company measures the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes on the consolidated statements of operations.
Stock Based Compensation	Stock Based CompensationStock-based compensation expense reflects the fair value of stock-based awards measured at the grant date and recognized over the relevant service period. The expense recognized includes the impact of forfeitures as they occur. The Company estimates the fair value of each stock-based award on the measurement date using either the current market price of the stock, the Black-Scholes option valuation model, or the Monte Carlo Simulation valuation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or restricted stock units, a risk-free interest rate and dividend yield. The Company recognizes stock-based compensation expense related to options, restricted stock units and market based performance stock units on a straight-line basis over the service period of the award, which is generally 4 years for options and restricted stock units and 3 years for market based performance stock units.
Foreign Currency Translation	Foreign Currency Translation The functional currency of the Company's foreign subsidiaries is the local currency in which the subsidiary operates. For foreign operations where the local currency is considered to be the functional currency, the Company translates assets and liabilities into U.S. dollars at the exchange rate on the balance sheet date. The Company translates income and expense items at average rates of exchange prevailing during each period. The Company accumulates translation adjustments in accumulated other comprehensive loss, a component of stockholders’ equity. Transaction gains or losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in other expense in the statements of operations as incurred.
Derivative Financial Instruments	Derivative Financial Instruments The Company is exposed to market risks, including changes in foreign currency and interest rates. The Company periodically enters into certain derivative financial instruments to hedge the underlying economic exposure. Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders’ equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the
Contingencies	Contingencies The Company is subject to various legal proceedings that arise in the ordinary course of business, including patent infringement and product liability matters. The Company records accruals for contingencies when it is probable the liability has been incurred and the amount can be reasonably estimated. Legal fees are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. These recoveries are not netted against the related liabilities for financial statement presentation.
Recently Issued Accounting Pronouncements	The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: Recently Issued Accounting Pronouncements - Adopted Standard Description Date Adopted Effect on the Consolidated Financial Statements ASU 2016-02, Leases (Topic 842) This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. June 1, 2019 Refer to Note 16, Leases, for the required disclosures related to adopting this standard. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2018-13, Fair Value Measurement (Topic 820) This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes. June 1, 2020 The Company plans to adopt the new standard in the first quarter of fiscal year 2021 and does not expect there to be a material impact to the consolidated financial statements. ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. June 1, 2020 The Company plans to adopt the new standard in the first quarter of fiscal year 2021 and does not expect there to be a material impact to the consolidated financial statements.
Revenue from Contract with Customer	REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue Recognition Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Contracts and Performance Obligations The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Transaction Price and Allocation to Performance Obligations Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately. Revenue Recognition Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract. In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer. The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. Sales, value added, and other taxes collected on behalf of third parties are excluded from revenue. Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the year ended May 31, 2020, such product returns were not material. Contract Balances with Customers A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying consolidated balance sheets. Costs to Obtain or Fulfill a Customer Contract Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.

Basis of Presentation, Busine_3

Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	May 31, 2020
Accounting Policies [Abstract]
Property, plant and equipment	Refer below for useful lives by category: Estimated useful lives Building and building improvements 39 years Machinery and equipment 5 to 8 years Computer software and equipment 3 to 5 years (in thousands) May 31, 2020 May 31, 2019 Building and building improvements $ 27,119 $ 24,535 Machinery and equipment 13,602 14,029 Computer software and equipment 24,730 24,980 Construction in progress 3,050 1,239 68,501 64,783 Less accumulated depreciation and amortization (40,661) (41,608) 27,840 23,175 Land and land improvements 472 1,083 $ 28,312 $ 24,258
Recent accounting pronouncements	The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: Recently Issued Accounting Pronouncements - Adopted Standard Description Date Adopted Effect on the Consolidated Financial Statements ASU 2016-02, Leases (Topic 842) This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. June 1, 2019 Refer to Note 16, Leases, for the required disclosures related to adopting this standard. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2018-13, Fair Value Measurement (Topic 820) This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes. June 1, 2020 The Company plans to adopt the new standard in the first quarter of fiscal year 2021 and does not expect there to be a material impact to the consolidated financial statements. ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. June 1, 2020 The Company plans to adopt the new standard in the first quarter of fiscal year 2021 and does not expect there to be a material impact to the consolidated financial statements.

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	May 31, 2020
Business Combinations [Abstract]
Schedule of estimated fair value of the assets acquired and liabilities assumed	The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired: (in thousands) Preliminary allocation Adjustments (1) Final allocation Accounts receivable $ 50 $ — $ 50 Inventory 150 — 150 Prepaid and other current assets 54 — 54 Long-term deposits 51 51 Property, plant and equipment 397 — 397 Intangible assets: Product technology 59,000 1,300 60,300 Goodwill 12,428 (1,001) 11,427 Total assets acquired $ 72,130 $ 299 $ 72,429 Liabilities assumed Accounts payable $ 84 $ — $ 84 Other current liabilities 615 — 615 Deferred tax liabilities 10,771 299 11,070 Total liabilities assumed $ 11,470 $ 299 $ 11,769 Net assets acquired $ 60,660 $ — $ 60,660 (1) Measurement period adjustments are recognized on a prospective basis in the period of change, instead of restating prior periods. There was no impact to reported earnings in connection with these measurement period adjustments for the periods presented. Amounts represent adjustments to the preliminary purchase price allocation first presented in the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2019 resulting from revising the Company's purchase price allocation for this acquisition. (in thousands) Final allocation Accounts receivable $ 900 Inventory 732 Prepaid and other current assets 98 Property, plant and equipment 133 Intangible assets: RadiaDyne trademark 400 OARtrac trademark 200 RadiaDyne legacy product technology 1,500 OARtrac product technology 18,900 RadiaDyne customer relationships 4,600 Goodwill 47,982 Total assets acquired $ 75,445 Liabilities assumed Accounts payable $ 352 Accrued expenses 106 Total liabilities assumed $ 458 Net assets acquired $ 74,987 (in thousands) Final allocation Inventory $ 50 Property, plant and equipment 10 Intangible assets: BioSentry trademark 2,500 BioSentry product technology 20,900 Customer relationships 2,600 Goodwill 13,740 Net assets acquired $ 39,800

Divestitures (Tables)

Divestitures (Tables)	12 Months Ended
	May 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations Disclosure	The following table summarizes the financial results of discontinued operations: Year ended May 31, (in thousands) 2019 2018 Net sales $ 88,850 $ 82,630 Cost of sales (exclusive of amortization) 52,978 49,611 Gross profit 35,872 33,019 Operating expenses Research and development 1,177 1,121 Sales and marketing 4,129 4,167 General and administrative 271 274 Amortization of intangibles 2,716 2,729 Total operating expenses 8,293 8,291 Operating income 27,579 24,728 Gain on divestiture 46,592 — Income from discontinued operations before income taxes 74,171 24,728 Income tax expense (1,685) (2,166) Income from discontinued operations $ 72,486 $ 22,562 (in thousands) Proceeds received from Divestiture $ 169,242 Working capital adjustment (612) Fluid Management assets: Inventories 11,029 Property, plant and equipment, net 16,624 Intangible assets, net 15,047 Goodwill 75,308 Total Fluid Management assets 118,008 Transaction costs for Divestiture (1) 4,030 Gain on sale of the Fluid Management business before income taxes $ 46,592 (1) Costs include advisory fees, legal fees and professional fees Proceeds from the sale of Fluid Management have been presented in the Consolidated Statements of Cash Flows under investing activities for the fiscal year ended May 31, 2019. Total operating and investing cash flows of discontinued operations for the fiscal year ended May 31, 2019 and 2018 are comprised of the following, which exclude the effect of income taxes: (in thousands) 2019 2018 Net cash provided by operating activities $ 2,245 $ 5,581 Net cash provided by investing activities 982 1,146

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	May 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the year ended May 31, 2020 and for the year ended May 31, 2019: Year ended May 31, 2020 Year ended May 31, 2019 (in thousands) United States International Total United States International Total Net sales Vascular Interventions & Therapies $ 98,965 $ 13,741 $ 112,706 $ 106,767 $ 13,134 $ 119,901 Vascular Access 76,768 17,531 94,299 79,611 15,119 94,730 Oncology 32,247 24,905 57,152 30,579 25,424 56,003 Total $ 207,980 $ 56,177 $ 264,157 $ 216,957 $ 53,677 $ 270,634
Contract with Customer, Asset and Liability	The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers: (in thousands) May 31, 2020 May 31, 2019 Receivables $ 31,263 $ 43,577 Contract assets $ — $ — Contract liabilities $ 545 $ 681

Fair Value of Financial Instr_2

Fair Value of Financial Instruments Fair Value of Financial Instruments (Tables)	12 Months Ended
	May 31, 2020
Fair Value Disclosures [Abstract]
Fair value of assets and liabilities measured on recurring basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurements using inputs considered as: (in thousands) Level 1 Level 2 Level 3 Fair Value at May 31, 2020 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 15,647 $ 15,647 Total Financial Liabilities $ — $ — $ 15,647 $ 15,647 Fair Value Measurements using inputs considered as: (in thousands) Level 1 Level 2 Level 3 Fair Value at May 31, 2019 Financial Liabilities Contingent consideration for acquisition earn out $ — $ — $ 13,486 $ 13,486 Total Financial Liabilities $ — $ — $ 13,486 $ 13,486
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	The table below presents the changes in fair value components of Level 3 instruments in the year ended May 31, 2020: Financial Liabilities (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance at May 31, 2019 $ 13,486 Contingent consideration liability recorded as a result of the acquisition (Note 2) 14,900 Change in present value of contingent consideration (1) (11,531) Contingent consideration payments (1,208) Balance at May 31, 2020 $ 15,647 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. The table below presents the changes in fair value components of Level 3 instruments in the year ended May 31, 2019: Financial Assets Financial Liabilities (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance at May 31, 2018 $ 1,317 $ 3,261 Contingent consideration liabilities recorded as a result of the acquisitions (Note 2) — 25,101 Change in fair value of contingent consideration (1) — (6,776) Fair market value adjustments 33 — Proceeds from sale of marketable securities (1,350) — Contingent consideration payments — (8,100) Balance at May 31, 2019 $ — $ 13,486
Fair Value, Liabilities Measured on Recurring Basis	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May 31, 2020: (in thousands) Fair Value Valuation Technique Unobservable Input Range Revenue based payments $ 14,811 Discounted cash flow Discount rate 5% Probability of payment 66% - 100% Projected fiscal year of payment 2024 - 2025 Technical milestones 836 Estimated probability Estimated probability 90% Projected year of payment 2021 $ 15,647

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	May 31, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following: (in thousands) May 31, 2020 May 31, 2019 Raw materials $ 23,308 $ 16,045 Work in process 8,318 6,786 Finished goods 28,279 17,240 Total $ 59,905 $ 40,071

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	12 Months Ended
	May 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses and other	Prepaid expenses and other consisted of the following: (in thousands) May 31, 2020 May 31, 2019 TSA receivable $ 2,911 $ — Software licenses 1,002 1,131 License fees 203 145 Trade shows 296 213 Rent 246 199 Other prepaid taxes 414 112 Other 2,238 2,203 Total $ 7,310 $ 4,003

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	May 31, 2020
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Refer below for useful lives by category: Estimated useful lives Building and building improvements 39 years Machinery and equipment 5 to 8 years Computer software and equipment 3 to 5 years (in thousands) May 31, 2020 May 31, 2019 Building and building improvements $ 27,119 $ 24,535 Machinery and equipment 13,602 14,029 Computer software and equipment 24,730 24,980 Construction in progress 3,050 1,239 68,501 64,783 Less accumulated depreciation and amortization (40,661) (41,608) 27,840 23,175 Land and land improvements 472 1,083 $ 28,312 $ 24,258

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	May 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	The changes in the carrying amount of goodwill for the year ended May 31, 2020 were as follows: (in thousands) Goodwill balance at May 31, 2019 $ 347,666 Additions for Eximo acquisition (Note 2) 11,427 Goodwill impairment (158,578) Goodwill balance at May 31, 2020 $ 200,515
Intangible assets	Intangible assets consisted of the following: May 31, 2020 (in thousands) Gross carrying Accumulated Net carrying Product technologies $ 251,569 $ (88,547) $ 163,022 Customer relationships 60,160 (30,018) 30,142 Trademarks 10,150 (6,691) 3,459 Licenses 6,087 (5,574) 513 $ 327,966 $ (130,830) $ 197,136 May 31, 2019 (in thousands) Gross carrying Accumulated Net carrying Product technologies $ 182,971 $ (75,412) $ 107,559 Customer relationships 60,166 (25,950) 34,216 Trademarks 9,300 (6,404) 2,896 Licenses 5,752 (5,036) 716 $ 258,189 $ (112,802) $ 145,387
Expected amortization expense	Annual amortization of these intangible assets is expected to approximate the following amounts for each of the next five fiscal years: (in thousands) 2021 $ 18,604 2022 18,001 2023 17,941 2024 16,369 2024 17,221 2025 and thereafter 109,000 $ 197,136

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	May 31, 2020
Income Tax Disclosure [Abstract]
Components of income (loss) before income tax provision	The components of loss from continuing operations before income tax benefit are as follows: Year ended May 31, (in thousands) 2020 2019 2018 Loss from continuing operations before tax expense: U.S. $ (166,984) $ (15,593) $ (18,454) Non-U.S. (1,151) 891 1,191 $ (168,135) $ (14,702) $ (17,263)
Summary of Income tax (benefit) provision analyzed by category	Income tax benefit is comprised of the following: Year ended May 31, (in thousands) 2020 2019 2018 Current Federal $ — $ — $ (148) State and local 96 128 152 Non U.S. 124 289 73 220 417 77 Deferred (1,568) (3,973) (11,113) Income tax benefit $ (1,348) $ (3,556) $ (11,036)
Summary of deferred tax asset and liabilities	Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows: (in thousands) May 31, 2020 May 31, 2019 Deferred tax assets Net operating loss carryforward $ 26,697 $ 18,955 Stock-based compensation 2,923 3,395 Federal and state R&D tax credit carryforward 5,412 4,259 Inventories 1,071 971 Expenses incurred not currently deductible 1,927 1,337 Accrued liabilities 95 139 Gross deferred tax asset 38,125 29,056 Deferred tax liabilities Depreciation and amortization 49,023 31,878 49,023 31,878 Valuation allowance (13,114) (11,688) Net deferred tax liability $ (24,012) $ (14,510)
Summary of Income tax rate reconciliation	The Company's consolidated income tax expense has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to the Company's income before income taxes for the following reasons: Year ended May 31, (in thousands) 2020 2019 2018 Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 28.6%, respectively $ (35,308) $ (3,087) $ (4,941) State income taxes, net of Federal tax benefit (40) (177) 120 Impact of Non-U.S. operations (81) 76 (288) Research and development tax credit (1,152) (936) (951) Impact of tax reform — — 12,860 Meals and entertainment 171 190 242 Goodwill impairment 33,301 — — Non-deductible interest on contingent payments 99 — — Non-taxable gain on revaluation of contingent consideration liability (118) — — Change in valuation allowance 1,426 175 (18,526) Effect of elimination of stock compensation APIC pool 162 — — Other 192 203 448 Income tax benefit $ (1,348) $ (3,556) $ (11,036)
Summary of unrecognized tax benefits reconciliation	The following table provides a reconciliation of the beginning and ending amount of unrecognized tax benefits: Year ended May 31, (in thousands) 2020 2019 2018 Unrecognized tax benefits balance at June 1 $ 464 $ 464 $ 899 Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform — — (287) Decrease due to lapse in statute of limitations — — (148) Unrecognized tax benefits balance at May 31 $ 464 $ 464 $ 464

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	May 31, 2020
Payables and Accruals [Abstract]
Accrued liabilities	Accrued liabilities consist of the following: (in thousands) May 31, 2020 May 31, 2019 Payroll and related expenses $ 13,059 $ 14,987 Royalties 2,392 2,088 Accrued severance 794 504 Sales and franchise taxes 634 807 Outside services 2,222 3,514 Litigation matters (Note 17) — 2,700 Indemnification holdback 5,000 4,807 Other 5,279 8,931 Total $ 29,380 $ 38,338

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	May 31, 2020
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares	The following table reconciles basic to diluted weighted average shares outstanding for the years ended May 31, 2020, 2019 and 2018: Year ended May 31, 2020 2019 2018 Basic 37,961,224 37,484,573 37,074,797 Effect of dilutive securities — — — Diluted 37,961,224 37,484,573 37,074,797 Securities excluded as their inclusion would be anti-dilutive 2,581,006 2,200,318 1,077,256

Leases (Tables)

Leases (Tables)	12 Months Ended
	May 31, 2020
Leases [Abstract]
Supplemental balance sheet information	The following table presents supplemental balance sheet information related to leases: (in thousands) Balance Sheet Location May 31, 2020 Assets Operating lease ROU asset Other assets $ 10,146 Liabilities Current operating lease liabilities Other current liabilities 2,077 Non-current operating lease liabilities Other long-term liabilities 8,345 Total lease liabilities $ 10,422 May 31, 2020 Weighted average remaining term (in years) 5.00 Weighted average discount rate 4.2 %
Lease liability schedule	The following table presents the maturities of the lease liabilities: (in thousands) May 31, 2020 2021 $ 2,466 2022 2,357 2023 2,403 2024 1,864 2025 1,259 2026 and thereafter 1,188 Total lease payments $ 11,537 Less: Imputed Interest 1,115 Total lease obligations $ 10,422 Less: Current portion of lease obligations 2,077 Long-term lease obligations $ 8,345
Supplemental cash flow information	As of May 31, 2020, the expenses on the Consolidated Statement of Operations were classified as follows: (in thousands) May 31, 2020 Cost of sales $ 1,138 Research and development 583 Sales and marketing 397 General and administrative 1,233 $ 3,351 The following table presents supplemental cash flow and other information related to leases for the year ended: (in thousands) May 31, 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 2,372 ROU assets obtained in exchange for lease liabilities Operating leases 6,918
Future annual payments under non-cancelable operating leases	Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows: (in thousands) May 31, 2019 2020 $ 2,920 2021 2,338 2022 2,133 2023 2,131 2024 and thereafter 3,227 Total lease payments $ 12,749

Commitments And Contingencies (

Commitments And Contingencies (Tables)	12 Months Ended
	May 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Other commitments and contingencies	The following table summarizes the Company's other future commitments and contingencies as of May 31, 2020: (in thousands) Total 2021 2022 2023 2024 2025 and thereafter Purchase obligations (1) $ 553 $ 553 $ — $ — $ — $ — Royalties (2) 51,500 3,800 3,800 3,800 3,800 36,300 $ 52,053 $ 4,353 $ 3,800 $ 3,800 $ 3,800 $ 36,300 (1) The non-cancelable inventory purchase obligations are not reflected on the consolidated balance sheets under accounting principles generally accepted in the United States of America. (2) These are future minimum royalty payments.

Segments and Geographic Infor_2

Segments and Geographic Information (Tables)	12 Months Ended
	May 31, 2020
Segment Reporting [Abstract]
Summary of total net sales by product category	Total sales by product category are summarized below: Year ended May 31, (in thousands) 2020 2019 2018 Net sales by Product Category Vascular Interventions & Therapies $ 112,706 $ 119,901 $ 119,704 Vascular Access 94,299 94,730 92,760 Oncology/Surgery 57,152 56,003 49,191 Total $ 264,157 $ 270,634 $ 261,655
Summary of net sales for geographic areas	Total sales for geographic areas are summarized below: Year ended May 31, (in thousands) 2020 2019 2018 Net sales by Geography United States $ 207,980 $ 216,957 $ 213,727 International 56,177 53,677 47,928 Total $ 264,157 $ 270,634 $ 261,655

Acquisition, Restructuring an_2

Acquisition, Restructuring and Other Items, net (Tables)	12 Months Ended
	May 31, 2020
Restructuring and Related Activities [Abstract]
Acquisition, Restructuring and Other Items, net	Acquisition, restructuring and other items, net consisted of: Year ended May 31, (in thousands) 2020 2019 2018 Legal (1) $ 2,666 $ 7,802 $ 8,407 Mergers and acquisitions (2) 782 4,030 1,660 Transition service agreement (3) (1,799) — — Divestiture (4) 2,809 — — Intangible and other asset impairment — 1,704 — Restructuring 26 289 4,674 Other 1,530 1,302 691 Total $ 6,014 $ 15,127 $ 15,432 (1) Legal expenses related to litigation that is outside the normal course of business. (2) Mergers and acquisitions expenses related to investment banking, legal and due diligence. (3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business. (4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY. Contract Termination Plant Regulatory Cancellation Other (in thousands) Benefits Consolidation Filings Costs Costs Total Balance at May 31, 2017 $ 851 $ 111 $ — $ — $ — $ 962 Charges 1,440 2,892 68 200 74 4,674 Non-cash adjustments — (276) — — — (276) Cash payments (1,453) (2,706) (56) — (74) (4,289) Balance at May 31, 2018 $ 838 $ 21 $ 12 $ 200 $ — $ 1,071 Charges — 244 44 — — 288 Non-cash adjustments — — — (9) — (9) Cash payments (838) (265) (44) (191) — (1,338) Balance at May 31, 2019 $ — $ — $ 12 $ — $ — $ 12 Charges — — 26 — — 26 Cash payments — — (38) — — (38) Balance at May 31, 2020 $ — $ — $ — $ — $ — $ —

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	May 31, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows for fiscal years 2020 and 2019: (in thousands) Foreign currency translation gain (loss) Unrealized gain (loss) on marketable securities Total Balance at May 31, 2018 $ (1,035) $ 83 $ (952) Other comprehensive income before reclassifications, net of tax (317) 33 (284) Amounts reclassified from accumulated other comprehensive income — (116) (116) Net other comprehensive income $ (317) $ (83) $ (400) Balance at May 31, 2019 $ (1,352) $ — $ (1,352) Other comprehensive income (loss) before reclassifications, net of tax 11 — 11 Net other comprehensive loss $ 11 $ — $ 11 Balance at May 31, 2020 $ (1,341) $ — $ (1,341)

Basis of Presentation, Busine_4

Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	May 31, 2020
Business Acquisition [Line Items]
Maturity period	less than three months
Employee Stock Option
Business Acquisition [Line Items]
Period of recognition for costs not yet recognized (years)	4 years
Restricted Stock
Business Acquisition [Line Items]
Period of recognition for costs not yet recognized (years)	3 years
Minimum
Business Acquisition [Line Items]
Accounts receivables period due	30 days
Estimated useful life of intangible assets other than goodwill (years)	2 years
Maximum
Business Acquisition [Line Items]
Accounts receivables period due	90 days
Estimated useful life of intangible assets other than goodwill (years)	18 years
Building and building improvements
Business Acquisition [Line Items]
Useful life (years)	39 years
Machinery and equipment | Minimum
Business Acquisition [Line Items]
Useful life (years)	5 years
Machinery and equipment | Maximum
Business Acquisition [Line Items]
Useful life (years)	8 years
Computer software and equipment | Minimum
Business Acquisition [Line Items]
Useful life (years)	3 years
Computer software and equipment | Maximum
Business Acquisition [Line Items]
Useful life (years)	5 years

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Thousands	Dec. 17, 2019	Oct. 02, 2019	Sep. 21, 2018	Aug. 14, 2018	May 31, 2020	May 31, 2019	Nov. 30, 2019
Business Acquisition [Line Items]
Other long-term liabilities					$ 9,029	$ 521
Accrued liabilities					$ 29,380	38,338
C3 Wave Tip Location Asset
Business Acquisition [Line Items]
Aggregate purchase price	$ 10,000
Contingent consideration for acquisition earn outs	5,000
Inventory	$ 600
Estimated useful life of intangible assets other than goodwill (years)	15 years
Trademarks | C3 Wave Tip Location Asset
Business Acquisition [Line Items]
Finite-lived intangibles	$ 900
Product technology | C3 Wave Tip Location Asset
Business Acquisition [Line Items]
Finite-lived intangibles	$ 8,500
Minimum
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)					2 years
Maximum
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)					18 years
Eximo Medical, Ltd.
Business Acquisition [Line Items]
Aggregate purchase price		$ 60,700
Payments to acquire business		45,800
Revenue based payments		$ 14,900
Inventory					$ 150		$ 150
Eximo Medical, Ltd. | Product technology
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)					15 years
Intangible assets					$ 60,300		$ 59,000
RadiaDyne
Business Acquisition [Line Items]
Aggregate purchase price			$ 75,000
Payments to acquire business			47,900
Revenue based payments			22,300
Acquisition related costs					$ 600	1,600
Inventory						732
Other long-term liabilities			4,600
Accrued liabilities			$ 200
RadiaDyne | Customer relationships
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)			15 years
Intangible assets						4,600
RadiaDyne | Minimum | Trademarks
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)			5 years
RadiaDyne | Minimum | Product technology
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)			7 years
RadiaDyne | Maximum | Trademarks
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)			7 years
RadiaDyne | Maximum | Product technology
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)			10 years
RadiaDyne | Revenue milestones
Business Acquisition [Line Items]
Revenue based payments			$ 16,500
RadiaDyne | Technical Milestones
Business Acquisition [Line Items]
Revenue based payments			$ 5,800
BioSentry
Business Acquisition [Line Items]
Aggregate purchase price				$ 39,800
Payments to acquire business				37,000
Revenue based payments				$ 2,800
Acquisition related costs						1,000
Inventory						50
BioSentry | Trademarks
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)				15 years
Intangible assets						2,500
BioSentry | Product technology
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)				15 years
Intangible assets						20,900
BioSentry | Customer relationships
Business Acquisition [Line Items]
Estimated useful life of intangible assets other than goodwill (years)				10 years
Intangible assets						$ 2,600

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	6 Months Ended
	May 31, 2020	Nov. 30, 2019	May 31, 2019
Assets acquired
Goodwill	$ 200,515		$ 347,666
Eximo Medical, Ltd.
Assets acquired
Accounts receivable	50	$ 50
Inventory	150	150
Prepaid expenses and other current assets	54	54
Long-term deposits	51	51
Property, plant and equipment	397	397
Goodwill	11,427	12,428
Goodwill, adjustments	(1,001)
Total assets acquired	72,429	72,130
Total assets acquired, adjustments	299
Liabilities assumed
Accounts payable	84	84
Other current liabilities	615	615
Deferred tax liabilities	11,070	10,771
Deferred tax liabilities, adjustments	299
Total liabilities assumed	11,769	11,470
Total liabilities assumed, adjustments	299
Net assets acquired	60,660	60,660
Net assets acquired, adjustments	0
Eximo Medical, Ltd. | Product technology
Assets acquired
Intangible assets	60,300	$ 59,000
Intangible assets, adjustments	$ 1,300
RadiaDyne
Assets acquired
Accounts receivable			900
Inventory			732
Prepaid expenses and other current assets			98
Property, plant and equipment			133
Goodwill			47,982
Total assets acquired			75,445
Liabilities assumed
Accounts payable			352
Accrued expenses			106
Total liabilities assumed			458
Net assets acquired			74,987
RadiaDyne | RadiaDyne trademark
Assets acquired
Intangible assets			400
RadiaDyne | OarTrac trademark
Assets acquired
Intangible assets			200
RadiaDyne | RadiaDyne legacy product technology
Assets acquired
Intangible assets			1,500
RadiaDyne | OarTrac product technology
Assets acquired
Intangible assets			18,900
RadiaDyne | Customer relationships
Assets acquired
Intangible assets			4,600
BioSentry
Assets acquired
Inventory			50
Property, plant and equipment			10
Goodwill			13,740
Liabilities assumed
Net assets acquired			39,800
BioSentry | Trademarks
Assets acquired
Intangible assets			2,500
BioSentry | Product technology
Assets acquired
Intangible assets			20,900
BioSentry | Customer relationships
Assets acquired
Intangible assets			$ 2,600

Divestitures (Details)

Divestitures (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2019	May 31, 2018
NAMIC Fluid Management Business | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received		$ 169,200	$ 169,200
Gain on divestiture		46,600	46,592	$ 0
Working capital adjustments		$ 600	612
Intraperiod tax allocation income tax expense			1,600
Tax effect of gain on divestiture			$ 600
Medline
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Term of transition services agreement (months)	24 months

Divestitures - Tables (Details)

Divestitures - Tables (Details) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Aug. 31, 2018	May 31, 2020	May 31, 2019	May 31, 2018
Income Statement [Abstract]
Income from discontinued operations	$ 56,120	$ 5,405	$ 5,727	$ 5,235	$ 0	$ 72,486	$ 22,562
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Proceeds received from Divestiture					0	169,242	0
Transaction costs for Divestiture					$ 0	(4,030)	0
NAMIC Fluid Management Business | Discontinued Operations, Disposed of by Sale
Income Statement [Abstract]
Net sales						88,850	82,630
Cost of sales (exclusive of amortization)						52,978	49,611
Gross profit						35,872	33,019
Research and development						1,177	1,121
Sales and marketing						4,129	4,167
General and administrative						271	274
Amortization of intangibles						2,716	2,729
Total operating expenses						8,293	8,291
Operating income						27,579	24,728
Gain on divestiture	46,600					46,592	0
Income from discontinued operations before income taxes						74,171	24,728
Income tax expense						(1,685)	(2,166)
Income from discontinued operations						72,486	22,562
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Proceeds received from Divestiture						169,242
Working capital adjustment	(600)					(612)
Inventories	11,029					11,029
Property, plant and equipment, net	16,624					16,624
Disposal Group, Including Discontinued Operation, Intangible Assets	15,047					15,047
Goodwill	75,308					75,308
Total Fluid Management assets	118,008					118,008
Transaction costs for Divestiture						4,030
Gain on sale of the Fluid Management business before income taxes	$ 46,600					$ 46,592	$ 0

Divestitures - Cash Flows (Deta

Divestitures - Cash Flows (Details) - NAMIC Fluid Management Business - Discontinued Operations, Disposed of by Sale - USD ($) $ in Thousands	12 Months Ended
	May 31, 2019	May 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net cash provided by operating activities	$ 2,245	$ 5,581
Net cash provided by investing activities	$ 982	$ 1,146

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Aug. 31, 2018	May 31, 2020	May 31, 2019	May 31, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 58,332	$ 69,780	$ 70,003	$ 66,042	$ 71,182	$ 65,524	$ 69,985	$ 63,943	$ 264,157	$ 270,634	$ 261,655
United States
Disaggregation of Revenue [Line Items]
Net sales									207,980	216,957	$ 213,727
International
Disaggregation of Revenue [Line Items]
Net sales									56,177	53,677
Vascular Interventions & Therapies
Disaggregation of Revenue [Line Items]
Net sales									112,706	119,901
Vascular Interventions & Therapies | United States
Disaggregation of Revenue [Line Items]
Net sales									98,965	106,767
Vascular Interventions & Therapies | International
Disaggregation of Revenue [Line Items]
Net sales									13,741	13,134
Vascular Access
Disaggregation of Revenue [Line Items]
Net sales									94,299	94,730
Vascular Access | United States
Disaggregation of Revenue [Line Items]
Net sales									76,768	79,611
Vascular Access | International
Disaggregation of Revenue [Line Items]
Net sales									17,531	15,119
Oncology
Disaggregation of Revenue [Line Items]
Net sales									57,152	56,003
Oncology | United States
Disaggregation of Revenue [Line Items]
Net sales									32,247	30,579
Oncology | International
Disaggregation of Revenue [Line Items]
Net sales									$ 24,905	$ 25,424

Revenue from Contracts with C_4

Revenue from Contracts with Customers (Details) - USD ($) $ in Millions	12 Months Ended
	May 31, 2020	May 31, 2019
Revenue from External Customer [Line Items]
Right of return period (days)	30 days
Restocking charge (percent)	20.00%
Restocking charge period (months)	12 months
Revenue recognized from contract liabilities	$ 2.2	$ 1.1
Additions to contract liabilities	$ 2.1	$ 0.6
Minimum
Revenue from External Customer [Line Items]
Performance obligation payment term (days)	30 days
Maximum
Revenue from External Customer [Line Items]
Performance obligation payment term (days)	90 days

Revenue from Contracts with C_5

Revenue from Contracts with Customers Revenue from Contracts with Customers - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Revenue from Contract with Customer [Abstract]
Receivables	$ 31,263	$ 43,577
Contract assets	0	0
Contract liabilities	$ 545	$ 681

Fair Value of Financial Instr_3

Fair Value of Financial Instruments Fair Value of Financial Instruments (Details) - Recurring - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Financial Liabilities
Contingent consideration for acquisition earn outs	$ 15,647	$ 13,486
Total Financial Liabilities	15,647	13,486
Level 1
Financial Liabilities
Contingent consideration for acquisition earn outs	0	0
Total Financial Liabilities	0	0
Level 2
Financial Liabilities
Contingent consideration for acquisition earn outs	0	0
Total Financial Liabilities	0	0
Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs	15,647	13,486
Total Financial Liabilities	$ 15,647	$ 13,486

Fair Value of Financial Instr_4

Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 2) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2020	May 31, 2019	May 31, 2018
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance			$ 0	$ 1,317
Contingent consideration liabilities recorded as a result of the acquisitions (Note 2)				0
Change in present value of contingent consideration				0
Fair market value adjustments				33
Proceeds from sale of marketable securities				(1,350)
Contingent consideration payments				0
Ending balance		$ 0		0	$ 1,317
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance			13,486	3,261
Contingent consideration liabilities recorded as a result of the acquisitions (Note 2)			14,900	25,101
Change in fair value of contingent consideration			(11,531)	(6,776)	250
Fair market value adjustments				0
Proceeds from sale of marketable securities				0
Contingent consideration payments			(1,208)	(8,100)
Ending balance	$ 15,647	13,486	$ 15,647	$ 13,486	$ 3,261
Lower Projected Sales Volume Over The Contractual Earn Out Period
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Gain from reduction in fair value of contingent liability	9,200	$ 8,400
Technical Milestones
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Gain from reduction in fair value of contingent liability	$ 2,700

Fair Value of Financial Instr_5

Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 3) $ in Thousands	May 31, 2020USD ($)	May 31, 2020USD ($)	May 31, 2020USD ($)	May 31, 2019USD ($)	May 31, 2018USD ($)
Summary showing the recurring fair value measurements of the contingent consideration liability
Goodwill impairment	$ 158,600	$ 158,600	$ 158,578	$ 0	$ 0
Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Revenue based payments	15,647	15,647	15,647	13,486
Total financial liabilities	15,647	15,647	15,647	13,486
Minimum
Summary showing the recurring fair value measurements of the contingent consideration liability
Potential amount of undiscounted future contingent consideration	21,000	21,000	21,000
Level 3 | Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Revenue based payments	15,647	15,647	15,647	13,486
Total financial liabilities	15,647	15,647	15,647	$ 13,486
Revenue based payments | Valuation Technique, Discounted Cash Flow | Level 3 | Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Revenue based payments	$ 14,811	$ 14,811	$ 14,811
Revenue based payments | Valuation Technique, Discounted Cash Flow | Level 3 | Recurring | Discount Rate
Summary showing the recurring fair value measurements of the contingent consideration liability
Discount rate used in fair value calculation	5	5	5
Revenue based payments | Valuation Technique, Discounted Cash Flow | Level 3 | Minimum | Recurring | Measurement Input, Probability of Payment
Summary showing the recurring fair value measurements of the contingent consideration liability
Discount rate used in fair value calculation	0.66	0.66	0.66
Revenue based payments | Valuation Technique, Discounted Cash Flow | Level 3 | Maximum | Recurring | Measurement Input, Probability of Payment
Summary showing the recurring fair value measurements of the contingent consideration liability
Discount rate used in fair value calculation	1	1	1
Technical Milestones | Valuation Technique, Estimated Probability | Level 3 | Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Revenue based payments	$ 836	$ 836	$ 836
Discount rate used in fair value calculation	0.90	0.90	0.90
Contingent Consideration Earn Out Liability | Level 3 | Recurring
Summary showing the recurring fair value measurements of the contingent consideration liability
Total financial liabilities	$ 15,647	$ 15,647	$ 15,647

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Inventories
Raw materials	$ 23,308	$ 16,045
Work in process	8,318	6,786
Finished goods	28,279	17,240
Total	59,905	40,071
Inventory valuation reserve	$ 4,700	$ 4,200

Prepaid Expenses and Other (Det

Prepaid Expenses and Other (Details) - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Prepaid expenses and other
TSA receivable	$ 2,911	$ 0
Software licenses	1,002	1,131
License fees	203	145
Trade shows	296	213
Rent	246	199
Other prepaid taxes	414	112
Other	2,238	2,203
Total	$ 7,310	$ 4,003

Property, Plant, and Equipment,

Property, Plant, and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Property, plant and equipment
Property, plant and equipment	$ 68,501	$ 64,783
Less accumulated depreciation and amortization	(40,661)	(41,608)
Property, plant and equipment excluding land and land improvements	27,840	23,175
Land and land improvements	472	1,083
Property, plant and equipment, Net	28,312	24,258
Depreciation expense	3,300	3,100	$ 3,400
Building and building improvements
Property, plant and equipment
Property, plant and equipment	27,119	24,535
Machinery and equipment
Property, plant and equipment
Property, plant and equipment	13,602	14,029
Computer software and equipment
Property, plant and equipment
Property, plant and equipment	24,730	24,980
Construction in progress
Property, plant and equipment
Property, plant and equipment	$ 3,050	$ 1,239

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	May 31, 2020	May 31, 2020	May 31, 2020	May 31, 2019	May 31, 2018
Goodwill and Intangible Assets (Textual) [Abstract]
Goodwill impairment	$ 158,600	$ 158,600	$ 158,578	$ 0	$ 0
Amortization expense			$ 18,121	$ 17,056	$ 13,906

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Details) $ in Thousands	12 Months Ended
	May 31, 2020USD ($)
Goodwill [Roll Forward]
Goodwill	$ 347,666
Goodwill	200,515
BioSentry
Goodwill [Roll Forward]
Goodwill	13,740
Goodwill, Acquired During Period	11,427
RadiaDyne
Goodwill [Roll Forward]
Goodwill	$ 47,982

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Details 1) - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	$ 327,966	$ 258,189
Accumulated amortization	(130,830)	(112,802)
Net carrying value, finite-lived intangible assets	197,136	145,387
Product technologies
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	251,569	182,971
Accumulated amortization	(88,547)	(75,412)
Net carrying value, finite-lived intangible assets	163,022	107,559
Customer relationships
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	60,160	60,166
Accumulated amortization	(30,018)	(25,950)
Net carrying value, finite-lived intangible assets	30,142	34,216
Trademarks
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	10,150	9,300
Accumulated amortization	(6,691)	(6,404)
Net carrying value, finite-lived intangible assets	3,459	2,896
Licenses
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value, finite-lived intangible assets	6,087	5,752
Accumulated amortization	(5,574)	(5,036)
Net carrying value, finite-lived intangible assets	$ 513	$ 716

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Details 2) - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Expected amortization expense
2020	$ 18,604
2021	18,001
2022	17,941
2023	16,369
2024	17,221
2025 and thereafter	109,000
Net carrying value, finite-lived intangible assets	$ 197,136	$ 145,387

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Loss from continuing operations before tax expense:
U.S.	$ (166,984)	$ (15,593)	$ (18,454)
Non-U.S.	(1,151)	891	1,191
Income (loss) before tax expense	$ (168,135)	$ (14,702)	$ (17,263)

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Current
Federal	$ 0	$ 0	$ (148)
State and local	96	128	152
Non U.S.	124	289	73
Current	220	417	77
Deferred	(1,568)	(3,973)	(11,113)
Income tax benefit	$ (1,348)	$ (3,556)	$ (11,036)

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Deferred tax assets
Net operating loss carryforward	$ 26,697	$ 18,955
Stock-based compensation	2,923	3,395
Federal and state R&D tax credit carryforward	5,412	4,259
Inventories	1,071	971
Expenses incurred not currently deductible	1,927	1,337
Deferred revenue	95	139
Gross deferred tax asset	38,125	29,056
Deferred tax liabilities
Excess tax over book depreciation and amortization	49,023	31,878
Gross deferred tax liability	49,023	31,878
Valuation Allowance	(13,114)	(11,688)
Net deferred tax liability	$ (24,012)	$ (14,510)

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	May 31, 2020	May 31, 2020	May 31, 2020	May 31, 2019	May 31, 2018
Income Taxes (Textual) [Abstract]
Goodwill impairment	$ 158,600,000	$ 158,600,000	$ 158,578,000	$ 0	$ 0
Additional unrecognized tax benefit	500,000	500,000	500,000
Accrued interest and penalties	0	0	0
Eximo Medical, Ltd.
Income Taxes (Textual) [Abstract]
Deferred tax liability, purchase accounting adjustment	11,000,000	11,000,000	11,000,000
Federal
Income Taxes (Textual) [Abstract]
Net operating loss carryforwards after considering limitations of use	112,300,000	112,300,000	112,300,000
Tax Year 2022 and 2023 | Federal
Income Taxes (Textual) [Abstract]
Federal and State net operating loss carryforwards	8,600,000	8,600,000	8,600,000
Tax Year 2028 and 2037 | Federal
Income Taxes (Textual) [Abstract]
Net operating loss carryforwards after considering limitations of use	79,400,000	79,400,000	79,400,000
Indefinite | Federal
Income Taxes (Textual) [Abstract]
Net operating loss carryforwards after considering limitations of use	24,300,000	24,300,000	24,300,000
Indefinite | Israel
Income Taxes (Textual) [Abstract]
Federal and State net operating loss carryforwards	11,000,000	11,000,000	11,000,000
Tax Year 2020 To 2040 | State
Income Taxes (Textual) [Abstract]
Federal and State net operating loss carryforwards	$ 9,300,000	$ 9,300,000	$ 9,300,000

Income Taxes (Details 4)

Income Taxes (Details 4) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Reasons for consolidated income tax provision
Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 28.6%, respectively	$ (35,308)	$ (3,087)	$ (4,941)
State income taxes, net of Federal tax benefit	(40)	(177)	120
Impact of Non US operations	(81)	76	(288)
Research and development tax credit	(1,152)	(936)	(951)
Impact of tax reform	0	0	12,860
Meals and entertainment	171	190	242
Goodwill impairment	33,301	0	0
Nondeductible interest on contingent payments	99	0	0
Nontaxable gain on revaluation of contingent consideration liability	(118)	0	0
Change in valuation allowance	1,426	175	(18,526)
Effect of elimination of stock compensation APIC pool	162	0	0
Other	192	203	448
Income tax benefit	$ (1,348)	$ (3,556)	$ (11,036)

Income Taxes Income Taxes (Deta

Income Taxes Income Taxes (Details 5) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning balance	$ 464	$ 464	$ 899
Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform	0	0	(287)
Decrease due to lapse in statute of limitations	0	0	(148)
Unrecognized tax benefits, ending balance	$ 464	$ 464	$ 464

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	May 31, 2020	May 31, 2019
Accrued liabilities
Payroll and related expenses	$ 13,059	$ 14,987
Royalties	2,392	2,088
Accrued severance	794	504
Sales and franchise taxes	634	807
Outside services	2,222	3,514
Litigation matters (Note 17)	0	2,700
Indemnification holdback	5,000	4,807
Other	5,279	8,931
Total	$ 29,380	$ 38,338

Long Term Debt - Narrative (Det

Long Term Debt - Narrative (Detail) - Line of Credit	12 Months Ended
	May 31, 2020USD ($)covenant	Jun. 03, 2019USD ($)
Debt Instrument [Line Items]
Debt default interest rate increase (percentage)	2.00%
Debt instrument, maximum leverage ratio of total indebtedness to adjusted EBITDA	3
Debt instrument, maximum leverage ratio of total indebtedness to adjusted EBITDA, following material acquisitions	3.50
Minimum fixed charge coverage ratio	1.25
Minimum
Debt Instrument [Line Items]
Commitment fee (percentage)	0.20%
Maximum
Debt Instrument [Line Items]
Commitment fee (percentage)	0.25%
Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility borrowing capacity		$ 125,000,000
Possible increase in borrowing capacity		$ 75,000,000
Number of financial covenants | covenant	2
Borrowings outstanding	$ 40,000,000
Interest rate at period end (percentage)	1.43%
Revolving Credit Facility | Minimum | Base Rate
Debt Instrument [Line Items]
Stated interest rate (percent)	0.25%
Revolving Credit Facility | Minimum | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Stated interest rate (percent)	1.25%
Revolving Credit Facility | Maximum | Base Rate
Debt Instrument [Line Items]
Stated interest rate (percent)	0.75%
Revolving Credit Facility | Maximum | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Stated interest rate (percent)	1.75%

Retirement Plans (Details)

Retirement Plans (Details) - USD ($) $ in Millions	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Retirement Plans (Textual) [Abstract]
Matching contributions	$ 3.2	$ 3.6	$ 3.9

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual)	Oct. 10, 2018shares	Oct. 25, 2016shares	Oct. 29, 2014$ / sharesshares	May 31, 2020USD ($)Employeesworking_hour$ / sharesshares	May 31, 2019USD ($)$ / sharesshares	May 31, 2018USD ($)$ / sharesshares
Other Ownership Interests [Line Items]
Authorized capital stock (shares)			80,000,000
Shares of common stock (shares)			75,000,000	75,000,000	75,000,000
Common stock, par value (usd per share) | $ / shares			$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)			5,000,000	5,000,000	5,000,000
Preferred stock, par value (usd per share) | $ / shares			$ 0.01	$ 0.01	$ 0.01
Common stock, votes per share			1
Subsequent grants for directors vesting				33.33%
Subsequent grants for directors vesting period				3 years
Option grants in the period, weighted average grant date fair value (usd per share) | $ / shares				$ 5.46	$ 6.53	$ 4.95
Risk free interest rate				1.63%	2.78%	2.08%
Expected volatility rate				31.00%	31.00%	30.00%
Expected term				4 years 10 months 28 days	4 years 9 months 14 days	4 years 8 months 19 days
The total intrinsic value of options exercised | $				$ 500,000	$ 1,400,000	$ 700,000
Compensation not yet recognized | $				4,000,000
Proceeds from stock options exercised | $				600,000	1,500,000	2,000,000
Tax benefit | $				$ 1,700,000	$ 2,100,000	$ 1,800,000
Grants in the period, weighted average grant date fair value (usd per share) | $ / shares					$ 20.87	$ 16.60
Average price of share issued | $ / shares				$ 12.11	$ 16.08	$ 14.03
Employee Stock Option
Other Ownership Interests [Line Items]
Percentage of grants to employees vesting				25.00%
Option grants to employees vesting period				4 years
Period of recognition for costs not yet recognized (years)				4 years
Tax benefit | $				$ 0	$ 0	$ 0
Restricted Stock Units
Other Ownership Interests [Line Items]
Period of recognition for costs not yet recognized (years)				3 years
Vesting percentage (as percent)				25.00%
Vesting period				1 year
Grants in the period, weighted average grant date fair value (usd per share) | $ / shares				$ 20.35
Employee service, compensation cost not yet recognized | $				$ 5,700,000
Nonvested compensation, weighted average grant date fair value (usd per share) | $ / shares				$ 19.65	$ 18.60
Nonvested compensation (shares)				464,921	430,936
Performance Share and Restricted Stock Unit Awards
Other Ownership Interests [Line Items]
Total fair value of restricted stock awards vesting | $				$ 3,900,000	$ 4,600,000	$ 2,700,000
Performance Shares
Other Ownership Interests [Line Items]
Compensation not yet recognized | $				$ 2,000,000
Nonvested compensation, weighted average grant date fair value (usd per share) | $ / shares				$ 14.06	$ 28.62	$ 23.83
Performance period				3 years
Employee Stock Option
Other Ownership Interests [Line Items]
Period of recognition for costs not yet recognized (years)				3 years
2004 Stock and Incentive Award Plan
Other Ownership Interests [Line Items]
Total number of common stock reserved for issuance (shares)				7,750,000
Total number of common stock available to be issued (shares)				1,600,000
Options exercisable period				10 years
Incentive award plan to increase the minimum number of shares (shares)	750,000	250,000
2004 Stock and Incentive Award Plan | Maximum
Other Ownership Interests [Line Items]
Total number of common stock available to be issued (shares)				800,000
Stock Purchase Plan
Other Ownership Interests [Line Items]
Total number of common stock available to be issued (shares)				2,100,000
Maximum number of shares to be offered				3,500,000
Share purchase periods | Employees				2
Duration of purchase of shares				6 months
Employee eligible in participating in offering period				6 months
Number of working hours to be eligible (working hour) | working_hour				20
Number of working months to be eligible				5 months
Employees ownership threshold				5.00%
Percentage of fair market value of a share of common stock on the first day of the offering period				85.00%
Percentage of fair market value of a share of common stock on the last day of the offering period				85.00%
Number of additional shares reserved for issuance (shares)				1,000,000		500,000
Maximum number of shares to be offered under the Stock Purchase Plan				100,567	72,863	89,943

Stockholders' Equity (Details)

Stockholders' Equity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	May 31, 2020USD ($)$ / sharesshares
Schedule summarizes stock option activity
Shares Outstanding at beginning of year (shares) | shares	1,760,313
Shares Granted (shares) | shares	539,946
Shares Exercised (shares) | shares	(61,100)
Shares Forfeited (shares) | shares	(300,406)
Shares Expired (shares) | shares
Shares Outstanding at end of year (shares) | shares	1,938,753
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Outstanding at beginning of year (usd per share) | $ / shares	$ 16.54
Weighted average exercise price Granted (usd per share) | $ / shares	18.92
Weighted average exercise price Exercised (usd per share) | $ / shares	12.67
Weighted average exercise price Forfeited (usd per share) | $ / shares	17.81
Weighted average exercise price Expired (usd per share) | $ / shares
Weighted average exercise price, Outstanding at end of year (usd per share) | $ / shares	$ 16.89
Shares Options exercisable at year-end (shares) | shares	1,004,531
Shares Options expected to vest in future periods (shares) | shares	934,222
Weighted average exercise price, Options exercisable at year end (usd per share) | $ / shares	$ 15.63
Weighted average exercise price, Options expected to vest in future periods (usd per share) | $ / shares	$ 18.25
Weighted average remaining contractual life	6 years
Weighted average remaining contractual life, Option exercisable at year end	3 years 8 months 12 days
Weighted average remaining contractual life, Option expected to vest in future periods	8 years 4 months 24 days
Aggregate intrinsic value, Outstanding at end of year | $	$ 0
Aggregate intrinsic value, Options exercisable at year end | $	0
Aggregate intrinsic value, Option expected to vest in future periods | $	$ 0

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - $ / shares	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Weighted Average Grant-Date Fair Value
Weighted Average Grant-Date Fair Value, Granted (usd per share)		$ 20.87	$ 16.60
Restricted Stock Units
Shares
Non-Vested Stock Award Units Beginning Balance (shares)	430,936
Non-Vested Stock Award Units, Granted (shares)	278,064
Non-Vested Stock Award Units, Vested (shares)	(197,985)
Non-Vested Stock Award Units, Cancelled (shares)	(46,094)
Non-Vested Stock Award Units Ending Balance (shares)	464,921	430,936
Weighted Average Grant-Date Fair Value
Weighted Average Grant-Date Fair Value Beginning Balance (usd per share)	$ 18.60
Weighted Average Grant-Date Fair Value, Granted (usd per share)	20.35
Weighted Average Grant-Date Fair Value, Vested (usd per share)	19.75
Weighted Average Grant-Date Fair Value, Cancelled (usd per share)	19.68
Weighted Average Grant-Date Fair Value Ending Balance (usd per share)	$ 19.65	$ 18.60
Performance Shares
Shares
Non-Vested Stock Award Units Beginning Balance (shares)	538,605
Non-Vested Stock Award Units, Granted (shares)	111,594
Non-Vested Stock Award Units, Vested (shares)	(235,580)
Non-Vested Stock Award Units, Cancelled (shares)	(141,498)
Non-Vested Stock Award Units Ending Balance (shares)	273,121	538,605
Weighted Average Grant-Date Fair Value
Weighted Average Grant-Date Fair Value Beginning Balance (usd per share)	$ 21.55
Weighted Average Grant-Date Fair Value, Granted (usd per share)	14.06
Weighted Average Grant-Date Fair Value, Vested (usd per share)	21.68
Weighted Average Grant-Date Fair Value, Cancelled (usd per share)	20.86
Weighted Average Grant-Date Fair Value Ending Balance (usd per share)	$ 22.07	$ 21.55

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation pre tax amount	$ 7,593	$ 9,249	$ 7,912
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation pre tax amount	655	461	119
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation pre tax amount	971	724	554
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation pre tax amount	1,665	1,952	1,778
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation pre tax amount	$ 4,302	$ 6,112	$ 5,461

Earnings Per Share (Details)

Earnings Per Share (Details) - shares	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Earnings Per Share [Abstract]
Basic	37,961,224	37,484,573	37,074,797
Effect of dilutive securities	0	0	0
Diluted	37,961,224	37,484,573	37,074,797
Securities excluded as their inclusion would be anti-dilutive	2,581,006	2,200,318	1,077,256

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	May 31, 2020	May 31, 2020	May 31, 2019	May 31, 2018	Jun. 01, 2019
Lessee, Lease, Description [Line Items]
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201602Member		us-gaap:AccountingStandardsUpdate201609Member
Total lease liabilities	$ 10,422	$ 10,422
Operating lease ROU asset	10,146	10,146
Non-cash lease expense	$ 3,400	$ 3,351
Rent expense			$ 2,500	$ 2,800
Building | Seven Year Building Lease
Lessee, Lease, Description [Line Items]
Lease term (years)	7 years	7 years
Lease payments	$ 6,400	$ 6,400
Building | Two Year Building Lease
Lessee, Lease, Description [Line Items]
Lease term (years)	5 years	5 years
Lease payments	$ 1,500	$ 1,500
Accounting Standards Update 2016-02
Lessee, Lease, Description [Line Items]
Total lease liabilities					$ 5,600
Operating lease ROU asset					$ 5,600
Cost of sales
Lessee, Lease, Description [Line Items]
Non-cash lease expense		1,138
General and administrative
Lessee, Lease, Description [Line Items]
Non-cash lease expense		$ 1,233

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) $ in Thousands	May 31, 2020USD ($)
Leases [Abstract]
Operating lease ROU asset	$ 10,146
Less: Current portion of lease obligations	2,077
Long-term lease obligations	8,345
Total lease obligations	$ 10,422
Weighted average remaining term (in years)	5 years
Weighted average discount rate (percent)	4.20%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesNoncurrent

Leases - Liability Maturity Sch

Leases - Liability Maturity Schedule (Details) $ in Thousands	May 31, 2020USD ($)
Leases [Abstract]
2021	$ 2,466
2022	2,357
2023	2,403
2024	1,864
2025	1,259
2026 and thereafter	1,188
Total lease payments	11,537
Less: Imputed Interest	1,115
Total lease obligations	10,422
Less: Current portion of lease obligations	2,077
Long-term lease obligations	$ 8,345

Leases - Supplemental Statement

Leases - Supplemental Statement of Operations Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	May 31, 2020	May 31, 2020
Lessee, Lease, Description [Line Items]
Non-cash lease expense	$ 3,400	$ 3,351
Cost of sales
Lessee, Lease, Description [Line Items]
Non-cash lease expense		1,138
Research and development
Lessee, Lease, Description [Line Items]
Non-cash lease expense		583
Sales and marketing
Lessee, Lease, Description [Line Items]
Non-cash lease expense		397
General and administrative
Lessee, Lease, Description [Line Items]
Non-cash lease expense		$ 1,233

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) $ in Thousands	12 Months Ended
	May 31, 2020USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 2,372
Operating leases	$ 6,918

Leases - Prior Year Lease Matur

Leases - Prior Year Lease Maturities (Details) $ in Thousands	May 31, 2019USD ($)
Leases [Abstract]
2020	$ 2,920
2021	2,338
2022	2,133
2023	2,131
2024 and thereafter	3,227
Total lease payments	$ 12,749

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	May 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase obligation	$ 553
Purchase obligation, 2021	553
Purchase obligation, 2022	0
Purchase obligation, 2023	0
Purchase obligation, 2024	0
Purchase obligation, 2025 and thereafter	0
Royalties	51,500
Royalties, 2021	3,800
Royalties, 2022	3,800
Royalties, 2023	3,800
Royalties, 2024	3,800
Royalties, 2025 and thereafter	36,300
Total	52,053
Total, 2021	4,353
Total, 2022	3,800
Total, 2023	3,800
Total, 2024	3,800
Total, 2025 and thereafter	$ 36,300

Commitments and Coontingencies

Commitments and Coontingencies - Narrative (Detail) $ in Millions	Jun. 28, 2019USD ($)	Mar. 07, 2019patent	Mar. 29, 2016claim	Mar. 24, 2016claim	Mar. 11, 2016claim	Jun. 01, 2015motion	Jan. 11, 2012Petitionreexamination_appealclaim	Jan. 31, 2017reexamination_appeal	May 31, 2020claim	Nov. 04, 2019claim
C.R. Bard, Inc.
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents | Petition							3
The Utah Action
Loss Contingencies [Line Items]
Number of claims rejected (claim)			20	8	6		40
Number of reexaminations (reexamination appeal) | reexamination_appeal							3
Number of pending claims (claim)				10	10		41
Number of claims reversed (claim)				2	4
The Utah Action | C.R. Bard, Inc. | Pending Litigation
Loss Contingencies [Line Items]
Number of reexaminations (reexamination appeal) | reexamination_appeal								3
Number of claims reversed (claim) | reexamination_appeal								3
MedComp and Smiths Patent Action | C.R. Bard, Inc.
Loss Contingencies [Line Items]
Number of pending claims (claim)										2
The Delaware Action
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon		3				2
Construction Issues
Loss Contingencies [Line Items]
Number of pending claims (claim)									2
Merz North America Settlement
Loss Contingencies [Line Items]
Payments for legal settlement | $	$ 2.5

Segments and Geographic Infor_3

Segments and Geographic Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Aug. 31, 2018	May 31, 2020	May 31, 2019	May 31, 2018
Net sales by Product Category
Net sales	$ 58,332	$ 69,780	$ 70,003	$ 66,042	$ 71,182	$ 65,524	$ 69,985	$ 63,943	$ 264,157	$ 270,634	$ 261,655
Vascular Interventions & Therapies
Net sales by Product Category
Net sales									112,706	119,901	119,704
Vascular Access
Net sales by Product Category
Net sales									94,299	94,730	92,760
Oncology/Surgery
Net sales by Product Category
Net sales									$ 57,152	$ 56,003	$ 49,191

Segments and Geographic Infor_4

Segments and Geographic Information (Details 1) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Aug. 31, 2018	May 31, 2020	May 31, 2019	May 31, 2018
Net sales by Geography
Net sales	$ 58,332	$ 69,780	$ 70,003	$ 66,042	$ 71,182	$ 65,524	$ 69,985	$ 63,943	$ 264,157	$ 270,634	$ 261,655
United States
Net sales by Geography
Net sales									207,980	216,957	213,727
International
Net sales by Geography
Net sales									$ 56,177	$ 53,677	$ 47,928

Segments and Geographic Infor_5

Segments and Geographic Information (Details Textual)	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Segment Reporting [Abstract]
International sales percentage of total net sales	21.00%	20.00%	18.00%
Total assets are located within the United States	99.00%

Acquisition, Restructuring an_3

Acquisition, Restructuring and Other Items, net (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Restructuring Cost and Reserve [Line Items]
Total	$ 6,014	$ 15,127	$ 15,432
Legal
Restructuring Cost and Reserve [Line Items]
Total	2,666	7,802	8,407
Mergers and acquisitions
Restructuring Cost and Reserve [Line Items]
Total	782	4,030	1,660
Transition Service Agreement
Restructuring Cost and Reserve [Line Items]
Total	(1,799)	0	0
Divestiture
Restructuring Cost and Reserve [Line Items]
Total	2,809	0	0
Intangible and other asset impairment
Restructuring Cost and Reserve [Line Items]
Total	0	1,704	0
Restructuring
Restructuring Cost and Reserve [Line Items]
Total	26	289	4,674
Other
Restructuring Cost and Reserve [Line Items]
Total	$ 1,530	$ 1,302	$ 691

Acquisition, Restructuring an_4

Acquisition, Restructuring and Other Items, net (Details 1) - USD ($) $ in Thousands	12 Months Ended			40 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018	May 31, 2020	May 31, 2017
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 6,014	$ 15,127	$ 15,432
Restructuring charges	26	288	4,674
Restructuring reserve	0	12	1,071	$ 0	$ 962
Manchester, GA and Denmead, UK into Glens Falls and Queensbury, NY
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	300	4,700	$ 6,300
Legal
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	2,666	7,802	$ 8,407
Legal | Biolitec, Inc.
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 500	3,400
Legal | Merz Contract Termination
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net		$ 2,500

Acquisition, Restructuring an_5

Acquisition, Restructuring and Other Items, net (Details 2) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning of period	$ 12	$ 1,071	$ 962
Charges	26	288	4,674
Non-cash adjustments		(9)	(276)
Cash payments	(38)	(1,338)	(4,289)
Restructuring Reserve, end of period	0	12	1,071
Termination Benefits
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning of period	0	838	851
Charges	0	0	1,440
Non-cash adjustments		0	0
Cash payments	0	(838)	(1,453)
Restructuring Reserve, end of period	0	0	838
Plant Consolidation
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning of period	0	21	111
Charges	0	244	2,892
Non-cash adjustments		0	(276)
Cash payments	0	(265)	(2,706)
Restructuring Reserve, end of period	0	0	21
Regulatory Filings
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning of period	12	12	0
Charges	26	44	68
Non-cash adjustments		0	0
Cash payments	(38)	(44)	(56)
Restructuring Reserve, end of period	0	12	12
Contract Cancellation
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning of period	0	200	0
Charges	0	0	200
Non-cash adjustments		(9)	0
Cash payments	0	(191)	0
Restructuring Reserve, end of period	0	0	200
Other Costs
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning of period	0	0	0
Charges	0	0	74
Non-cash adjustments		0	0
Cash payments	0	0	(74)
Restructuring Reserve, end of period	$ 0	$ 0	$ 0

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 614,815	$ 542,595
Ending Balance	454,872	614,815
Foreign currency translation gain (loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(1,352)	(1,035)
Other comprehensive income before reclassifications, net of tax	11	(317)
Amounts reclassified from accumulated other comprehensive income		0
Total comprehensive income (loss), net of tax	11	(317)
Ending Balance	(1,341)	(1,352)
Unrealized gain (loss) on marketable securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	0	83
Other comprehensive income before reclassifications, net of tax	0	33
Amounts reclassified from accumulated other comprehensive income		(116)
Total comprehensive income (loss), net of tax	0	(83)
Ending Balance	0	0
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(1,352)	(952)
Other comprehensive income before reclassifications, net of tax	11	(284)
Amounts reclassified from accumulated other comprehensive income		(116)
Total comprehensive income (loss), net of tax	11	(400)
Ending Balance	$ (1,341)	$ (1,352)

Quarterly Information (unaudi_3

Quarterly Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	May 31, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Aug. 31, 2018	May 31, 2020	May 31, 2019	May 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Net sales		$ 58,332	$ 69,780	$ 70,003	$ 66,042	$ 71,182	$ 65,524	$ 69,985	$ 63,943	$ 264,157	$ 270,634	$ 261,655
Gross profit		30,212	40,299	41,544	38,217	41,332	38,163	40,552	35,953	150,272	156,000	143,856
Net income (loss) from continuing operations						2,753	(4,609)	(3,587)	(5,704)	(166,787)	(11,146)	(6,227)
Net income from discontinued operations						56,120	5,405	5,727	5,235	0	72,486	22,562
Net income (loss)		$ (157,067)	$ (5,709)	$ (2,736)	$ (1,275)	$ 58,873	$ 796	$ 2,140	$ (469)	$ (166,787)	$ 61,340	$ 16,335
Earnings Per Share [Abstract]
Continuing operations - basic (usd per share)						$ 0.07	$ (0.12)	$ (0.10)	$ (0.15)	$ (4.39)	$ (0.30)	$ (0.17)
Continuing operations - diluted (usd per share)						0.07	(0.12)	(0.10)	(0.15)	(4.39)	(0.30)	(0.17)
Discontinued operations - basic (usd per share)						1.49	0.14	0.15	0.14	0	1.93	0.61
Discontinued operations - diluted (usd per share)						1.47	0.14	0.15	0.14	0	1.93	0.61
Basic (usd per share)		$ (4.14)	$ (0.15)	$ (0.07)	$ (0.03)	1.57	0.02	0.06	(0.01)	(4.39)	1.64	0.44
Diluted (usd per share)		$ (4.14)	$ (0.15)	$ (0.07)	$ (0.03)	$ 1.54	$ 0.02	$ 0.06	$ (0.01)	$ (4.39)	$ 1.64	$ 0.44
Goodwill impairment	$ 158,600	$ 158,600								$ 158,578	$ 0	$ 0

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2020	May 31, 2019	May 31, 2018
Allowance for deferred tax asset
Valuation and Qualifying Accounts
Balance at Beginning of Year	$ 11,688	$ 26,607	$ 48,348
Additions - Charged to costs and expenses	1,426	0	0
Deductions	0	(14,919)	(21,741)
Balance at End of Period	13,114	11,688	26,607
Allowance for sales returns and doubtful accounts
Valuation and Qualifying Accounts
Balance at Beginning of Year	1,906	2,466	2,945
Additions - Charged to costs and expenses	1,218	393	608
Deductions	(974)	(953)	(1,087)
Balance at End of Period	$ 2,150	$ 1,906	$ 2,466